<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">F1000Res</journal-id><journal-id journal-id-type="iso-abbrev">F1000Res</journal-id><journal-id journal-id-type="pmc">F1000Research</journal-id><journal-title-group><journal-title>F1000Research</journal-title></journal-title-group><issn pub-type="epub">2046-1402</issn><publisher><publisher-name>F1000Research</publisher-name><publisher-loc>London, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27508057</article-id><article-id pub-id-type="pmc">4963207</article-id><article-id pub-id-type="doi">10.12688/f1000research.8363.1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group><subject>Articles</subject><subj-group><subject>Cellular Death &#x00026; Stress Responses</subject></subj-group><subj-group><subject>Control of Gene Expression</subject></subj-group><subj-group><subject>Genitourinary Cancers</subject></subj-group></subj-group></article-categories><title-group><article-title>The expanding regulatory universe of p53 in gastrointestinal
cancer</article-title><fn-group content-type="pub-status"><fn><p>[version 1; referees: 2 approved]</p></fn></fn-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fesler</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Ning</given-names></name><xref ref-type="aff" rid="a2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ju</surname><given-names>Jingfang</given-names></name><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a1">1</xref></contrib><aff id="a1">
<label>1</label>Translational Research Laboratory, Department of Pathology,
Stony Brook University, Stony Brook, USA</aff><aff id="a2">
<label>2</label>Department of Pharmacy, Dalian Medical University, Dalian,
China</aff></contrib-group><author-notes><corresp id="c1"><label>a</label><email xlink:href="mailto:Jingfang.Ju@stonybrookmedicine.edu">Jingfang.Ju@stonybrookmedicine.edu</email></corresp><fn fn-type="con"><p>Andrew Fesler, Ning Zhang and Jingfang Ju wrote the manuscript.</p></fn><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>26</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>5</volume><elocation-id>756</elocation-id><history><date date-type="accepted"><day>8</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2016 Fesler A et al.</copyright-statement><copyright-year>2016</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the
Creative Commons Attribution Licence, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="f1000research-5-8996.pdf"/><abstract><p>Tumor suppresser gene <italic>TP53</italic> is one of the most frequently deleted
or mutated genes in gastrointestinal cancers. As a transcription factor, p53
regulates a number of important protein coding genes to control cell cycle, cell
death, DNA damage/repair, stemness, differentiation and other key cellular
functions. In addition, p53 is also able to activate the expression of a number
of small non-coding microRNAs (miRNAs) through direct binding to the promoter
region of these miRNAs.&#x000a0; Many miRNAs have been identified to be potential tumor
suppressors by regulating key effecter target mRNAs. Our understanding of the
regulatory network of p53 has recently expanded to include long non-coding RNAs
(lncRNAs). Like miRNA, lncRNAs have been found to play important roles in cancer
biology.&#x000a0; With our increased understanding of the important functions of these
non-coding RNAs and their relationship with p53, we are gaining exciting new
insights into the biology and function of cells in response to various growth
environment changes. In this review we summarize the current understanding of
the ever expanding involvement of non-coding RNAs in the p53 regulatory network
and its implications for our understanding of gastrointestinal cancer.</p></abstract><kwd-group kwd-group-type="author"><kwd>p53</kwd><kwd>non-coding RNA</kwd><kwd>gastrointestinal cancer</kwd></kwd-group><funding-group><award-group id="fund-1"><funding-source>National Institute of Health</funding-source><award-id>R01CA155019</award-id></award-group><award-group id="fund-2"><funding-source>National Cancer Institute</funding-source><award-id>R33CA147966</award-id></award-group><funding-statement>This study was supported by National Institute of Health/National
Cancer Institute R01CA155019 (J. Ju), R33CA147966 (J. Ju).</funding-statement><funding-statement><italic>The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.</italic></funding-statement></funding-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The discovery of p53 is one of the most exciting events in biological research over
the past 30 years <sup><xref rid="ref-1" ref-type="bibr">1</xref>&#x02013; <xref rid="ref-3" ref-type="bibr">3</xref></sup>. The field of p53 research represents a large growing body of exciting
studies with over 75000 citations in PubMed. p53 is one of the most frequently
mutated or deleted tumor suppressor genes in gastrointestinal (GI) cancers which
represent nearly 30% of tumor incidences. It is well established that the classical
function of tumor suppressor gene p53 is to act as a transcription factor to
regulate its downstream protein coding genes in response to various growth
conditions and cellular stresses <sup><xref rid="ref-4" ref-type="bibr">4</xref>, <xref rid="ref-5" ref-type="bibr">5</xref></sup>. Most of the research effort in the past has been devoted to the regulatory
mechanism of transcriptional regulation of protein coding genes by p53. Independent
of its transcriptional function, p53 is also able to regulate cell death by
migrating directly to the mitochondria and interacting with B-cell lymphoma 2
(BCL-2) family member proteins to induce mitochondrial outer membrane permeability <sup><xref rid="ref-6" ref-type="bibr">6</xref></sup>. Limited attention has been devoted to other p53 functions such as RNA
binding and post-transcriptional control <sup><xref rid="ref-7" ref-type="bibr">7</xref></sup>. With the discovery of non-coding RNA such as microRNA (miRNA), we and others
have recognized the importance of post-transcriptional control mediated by
non-coding RNAs in cancer <sup><xref rid="ref-8" ref-type="bibr">8</xref>, <xref rid="ref-9" ref-type="bibr">9</xref></sup>. Post-transcriptional and translational controls mediated by RNA binding
proteins and non-coding RNAs provide cells with a great advantage in response to
acute growth environment changes such as genotoxic stress caused by chemo- and/or
radiation- therapy <sup><xref rid="ref-10" ref-type="bibr">10</xref>&#x02013; <xref rid="ref-12" ref-type="bibr">12</xref></sup>. Non-coding RNAs comprise nearly 97% of transcribed RNA molecules <sup><xref rid="ref-13" ref-type="bibr">13</xref></sup>. Much of the research efforts in the past decade concerning non-coding RNAs
have been focused on short non-coding RNAs such as miRNAs and piRNAs. However, with
advances in sequencing technology, now there is a growing body of evidence showing
that lncRNAs also contribute to gene regulation at multiple levels <sup><xref rid="ref-14" ref-type="bibr">14</xref>, <xref rid="ref-15" ref-type="bibr">15</xref></sup>. Perhaps not surprisingly, important interactions have been discovered
between the functions and regulation of these non-coding RNAs and p53. The
relationship between non-coding RNA and p53 has been revealed to be quite dynamic,
with p53 regulating the expression of some non-coding RNAs while other non-coding
RNAs can function to regulate p53. While our appreciation of the important functions
of non-coding RNA has grown, we have achieved a much better understanding of
non-coding RNAs in the p53 regulated mechanisms in cancer.</p></sec><sec><title>p53 and miRNAs</title><p>p53 is one of the most well studied tumor suppressor genes. Disruptions of p53
functions, via deletions or mutations are found in many different types of cancers,
including over 50% of colorectal cancers <sup><xref rid="ref-16" ref-type="bibr">16</xref>&#x02013; <xref rid="ref-18" ref-type="bibr">18</xref></sup>. The importance of p53 in cancers, is associated with its role as a
transcriptional activator or suppressor, by which it regulates the expression of
many essential genes. p53 function is crucial to maintain genome integrity and
stability. p53 has been called the &#x02018;guardian of the genome&#x02019; <sup><xref rid="ref-19" ref-type="bibr">19</xref></sup>. It can also act as an RNA-binding protein to modulate gene expression at the
post-transcriptional level. p53 binds to the 5'-UTR region of cyclin-dependent
kinase 4 (CDK4) to suppress translation and it has been shown to auto-regulate its
own translation by directly interacting with its own mRNA <sup><xref rid="ref-20" ref-type="bibr">20</xref>, <xref rid="ref-21" ref-type="bibr">21</xref></sup>.</p><p>miRNA are short non-coding RNA that are transcribed as primary miRNAs (pri-miRNA) <sup><xref rid="ref-22" ref-type="bibr">22</xref></sup>. The pri-miRNA is cleaved by Drosha to a 70 nucleotide stem-loop pre-miRNA.
Pre-miRNA is transported to the cytoplasm by Exportin 5 and further cleaved by RNAse
Dicer to a 20 to 25 base pair double stranded miRNA. miRNAs modulate expression of
target mRNAs by either perfect or imperfect base pairing mainly at the 3'-UTR
regions of mRNA transcripts to inhibit translation and/or promote mRNA degradation.
One particular miRNA can regulate multiple mRNA transcripts providing the
possibility for the regulation of multiple different cellular networks and pathways
by an individual miRNA <sup><xref rid="ref-23" ref-type="bibr">23</xref></sup>. There are also multiple miRNAs that can directly interact with one
particular mRNA. With the discovery of miRNAs and the fact that they can have
important roles in cancer biology, as well as the well-established function of p53
in cancer, we reasoned that there may be some interplay between the two and some of
these miRNAs may be involved in the p53 regulatory network. We first reported a
systematic analysis of miRNA profiles in colon cancer cell lines, HCT 116,
containing either wild type p53 or null p53 <sup><xref rid="ref-8" ref-type="bibr">8</xref></sup>. In this study, we also profiled actively translated mRNAs impacted by p53
loss, and bioinformatically identified putative p53-binding sites in nearly 40% of
miRNA promoter regions ( <italic>e.g.</italic> miR-34s, miR-192, miR-215, miR-194,
miR-502, miR-200c, miR-26a, miR-15) <sup><xref rid="ref-8" ref-type="bibr">8</xref></sup>. Many of these miRNAs were found to be directly regulated by p53 by us and
other groups, thus establishing the interplay between p53 and miRNA networks in
cancer <sup><xref rid="ref-24" ref-type="bibr">24</xref>&#x02013; <xref rid="ref-30" ref-type="bibr">30</xref></sup>.</p></sec><sec><title>miRNA regulation by p53</title><p>Research by us and other groups has clearly demonstrated that regulation of miRNA is
among the many important functions of p53 in the cell. The miRNAs that have been
shown to be regulated by p53 have important roles in regulating cellular pathways
and functions such as cell cycle, apoptosis and chemoresistance. Working with the
miRNAs we identified as having putative p53 binding sites in their promoter region
we validated that miR-26a was directly regulated by p53 in colon cancer <sup><xref rid="ref-8" ref-type="bibr">8</xref></sup>. miR-26a has been found to act as a tumor suppressor in mouse intestine <sup><xref rid="ref-31" ref-type="bibr">31</xref></sup>. In gastric cancer, miR-26a also seems to act as a tumor suppressor, by
targeting fibroblast growth factor 9 (FGF9) and inhibiting cell proliferation and
metastasis <sup><xref rid="ref-32" ref-type="bibr">32</xref></sup>. miR-34s are the most extensively investigated miRNAs shown to be directly
regulated by p53 in a number of different tumor types <sup><xref rid="ref-28" ref-type="bibr">28</xref></sup>. miR-34a regulation by p53 is important in p53 mediated apoptosis, with
inhibition of miR-34a reducing p53-induced apoptosis <sup><xref rid="ref-9" ref-type="bibr">9</xref></sup>. miR-34a suppresses the E2F transcription factor pathway, reducing cell cycle
progression. miR-34a contributes to apoptosis regulation in colon cancer through
targeting silent information regulator 1 (SIRT1). miR-34a also contributes to the
activation of both p53 and p21. These functions contribute to the tumor suppressor
role of miR-34a <sup><xref rid="ref-9" ref-type="bibr">9</xref>, <xref rid="ref-28" ref-type="bibr">28</xref>, <xref rid="ref-33" ref-type="bibr">33</xref>&#x02013; <xref rid="ref-35" ref-type="bibr">35</xref></sup>. miR-34 is directly regulated by p53 and is reduced in 36% of human
colorectal cancer tumor specimens <sup><xref rid="ref-33" ref-type="bibr">33</xref></sup>. p53 dependent expression of miR-34 also inhibits tumor progression by
disrupting an IL-6R/Stat3/miR-34a feedback loop <sup><xref rid="ref-36" ref-type="bibr">36</xref></sup>. miR-34s have also been demonstrated to be important in other GI tumor types <sup><xref rid="ref-37" ref-type="bibr">37</xref></sup>. In gastric cancer, miR-34 expression can activate tumor suppressor pathways
in cells that lack functional p53 as well as being able to inhibit tumorsphere
formation <sup><xref rid="ref-38" ref-type="bibr">38</xref></sup>. miR-34 is one of the best characterized miRNAs that is regulated by p53 and
has important functions in cancer, and thus not surprisingly, miR-34 based
anti-cancer therapy also represents one of the first miRNAs to enter into clinical
trials <sup><xref rid="ref-39" ref-type="bibr">39</xref></sup>.</p><p>Beyond miR-34 as the poster child of p53 regulated miRNA, there are other important
p53 regulated miRNAs. miR-192 and miR-215 have been shown by multiple groups to be
regulated by p53 and their expression levels were reduced in colorectal cancer <sup><xref rid="ref-25" ref-type="bibr">25</xref>, <xref rid="ref-29" ref-type="bibr">29</xref>, <xref rid="ref-40" ref-type="bibr">40</xref>, <xref rid="ref-41" ref-type="bibr">41</xref></sup>. miR-192 and miR-215 can induce cell cycle arrest and enhance p53 mediated
p21 expression when overexpressed in colon cancer cell lines. Our group has focused
our efforts on investigating the roles of miR-192 and miR-215 in colorectal cancer
with the interest of understanding chemoresistance mechanisms to 5-fluorouracil
(5-FU) and methotrexate (MTX). We discovered that p53 and miR-192 form a positive
feedback loop to regulate cell cycle and proliferation <sup><xref rid="ref-25" ref-type="bibr">25</xref></sup>. In addition, we discovered a key protein target of miR-192 is dihydrofolate
reductase (DHFR). DHFR is a protein therapeutic target of MTX. miR-192 also
suppresses the expression of 5-FU protein target thymidylate synthase (TYMS, TS).
These results have also been reported by another research group <sup><xref rid="ref-42" ref-type="bibr">42</xref></sup>. However, the function of miR-215 and miR-192 seems to be different in
gastric cancer. It has been reported that the expression of miR-215 is up-regulated
in gastric cancer and one of the key targets is tumor suppressor retinoblastoma gene
Rb1 <sup><xref rid="ref-43" ref-type="bibr">43</xref></sup>. Consistent with this, another report shows that miR-192 and miR-215 are
associated with gastric tumor invasion and lymph node metastasis <sup><xref rid="ref-44" ref-type="bibr">44</xref></sup>. It appears that depending on the cellular and disease context, miRNAs can
target different sets of mRNAs, as a result, they can function as either tumor
suppressors or oncogenes. The regulatory mechanism and function of miR-192/215 will
be quite unique in colorectal cancer vs. gastric cancer. One recent study
demonstrated the potential of miR-192, miR-215 and miR-194 as promising detection
biomarkers for Barrett's esophagus <sup><xref rid="ref-45" ref-type="bibr">45</xref></sup>, further supporting the importance of the p53 mediated miRNAs. miR-194 has
also been identified as a p53 regulated miRNA. In colon cancer, miR-194 targets
thrombospondin 1 (TSP-1) and is involved in promoting angiogenesis <sup><xref rid="ref-46" ref-type="bibr">46</xref></sup>. In gastric cancer, miR-194 has been shown to target E3 ubiquitin-protein
ligase RBX1 and decrease proliferation and migration <sup><xref rid="ref-47" ref-type="bibr">47</xref></sup>. In contrast to these miRNAs, we have identified a negative correlation
between miR-502 expression and p53, suggesting that rather than inducing the
expression of miR-502, p53 inhibits its expression in colon cancer. miR-502 plays a
role in regulating autophagy and proliferation in colon cancer cells <sup><xref rid="ref-24" ref-type="bibr">24</xref></sup>. miR-145 is also transcriptionally regulated by p53. miR-145 in turn
suppresses the expression of cMyc and cyclin-dependent kinase 6 (CDK6), to inhibit
cell proliferation and induce apoptosis <sup><xref rid="ref-48" ref-type="bibr">48</xref>, <xref rid="ref-49" ref-type="bibr">49</xref></sup>. miR-1204 is transcriptionally activated by p53 and also inhibits cellular
proliferation <sup><xref rid="ref-50" ref-type="bibr">50</xref></sup>.</p><p>In addition to wild type p53, mutant p53 also plays key roles in GI cancer. Studies
have demonstrated that the gain-of-function of mutant p53 is an important mechanism
for tumors to develop resistance and impacts tumor progression <sup><xref rid="ref-51" ref-type="bibr">51</xref>, <xref rid="ref-52" ref-type="bibr">52</xref></sup>. In fact, mutant p53 can directly influence miRNA expression by interacting
with miRNA promoters <sup><xref rid="ref-53" ref-type="bibr">53</xref>, <xref rid="ref-54" ref-type="bibr">54</xref></sup>. Mutant p53 exerts oncogenic functions and promotes epithelial-mesenchymal
transition (EMT) in endometrial cancer (EC) by directly binding to the promoter of
miR-130b, a negative regulator of zinc finger E-box-binding homeobox 1 (ZEB-1), and
inhibiting its transcription. miR-223 was recently found to be down-regulated
directly by mutant p53 proteins in breast and colon cancer cell lines <sup><xref rid="ref-55" ref-type="bibr">55</xref></sup>. Mutant p53 binds the miR-223 promoter and reduces its transcriptional
activity. Such regulation requires the transcriptional repressor ZEB-1. In addition,
miR-223 exogenous expression sensitizes breast and colon cancer cell lines
expressing mutant p53 to treatment with DNA-damaging drugs <sup><xref rid="ref-55" ref-type="bibr">55</xref></sup>. Let-7i has also been found to be regulated by mutant p53, inhibiting
invasion and migration <sup><xref rid="ref-54" ref-type="bibr">54</xref></sup>. These results suggest that it will be important to identify additional
miRNAs that are regulated by various mutant p53 proteins. <xref ref-type="table" rid="T1">Table 1</xref> summarizes some p53 regulated miRNAs in GI cancer.</p><table-wrap id="T1" orientation="portrait" position="anchor"><label>Table 1. </label><caption><title>p53 regulated miRNA in GI cancer.</title></caption><table frame="hsides" rules="groups" content-type="article-table"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1">miRNA</th><th align="center" valign="top" rowspan="1" colspan="1">Wtp53/Mutp53</th><th align="center" valign="top" rowspan="1" colspan="1">Transcriptional <break/>Target</th><th align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor/ <break/>Oncogene</th><th align="center" valign="top" rowspan="1" colspan="1">Function</th><th align="center" valign="top" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-26a</td><td align="center" valign="top" rowspan="1" colspan="1">Wt</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Proliferation <break/>&#x02193;Metastasis
<break/>&#x02191;Apoptosis</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-8" ref-type="bibr">8</xref>, <xref rid="ref-31" ref-type="bibr">31</xref>, <xref rid="ref-32" ref-type="bibr">32</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-34</td><td align="center" valign="top" rowspan="1" colspan="1">Wt</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Proliferation, &#x02191;Cell Cycle
<break/>Arrest, &#x02191;Apoptosis, <break/>&#x02191;Senescence, &#x02193;Tumor
<break/>Sphere Formation, <break/>&#x02193;EMT</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-9" ref-type="bibr">9</xref>, <xref rid="ref-28" ref-type="bibr">28</xref>, <xref rid="ref-33" ref-type="bibr">33</xref>&#x02013; <xref rid="ref-35" ref-type="bibr">35</xref>, <break/>
<xref rid="ref-38" ref-type="bibr">38</xref>, <xref rid="ref-110" ref-type="bibr">110</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-192/ <break/>miR-215</td><td align="center" valign="top" rowspan="1" colspan="1">Wt</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">*</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;/&#x02193;Proliferation,
<break/>&#x02191;/&#x02193;Chemosensitivity, <break/>&#x02191;Cell Cycle Arrest</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-25" ref-type="bibr">25</xref>, <xref rid="ref-29" ref-type="bibr">29</xref>, <xref rid="ref-42" ref-type="bibr">42</xref>, <xref rid="ref-44" ref-type="bibr">44</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-194</td><td align="center" valign="top" rowspan="1" colspan="1">Wt</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">*</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Proliferation, &#x02193;Migration/
<break/>Invasion, &#x02191;Angiogenesis</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-46" ref-type="bibr">46</xref>, <xref rid="ref-47" ref-type="bibr">47</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-502</td><td align="center" valign="top" rowspan="1" colspan="1">Wt</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Autophagy, &#x02191;Cell <break/>Cycle
Arrest</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-24" ref-type="bibr">24</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-145</td><td align="center" valign="top" rowspan="1" colspan="1">Wt</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Proliferation</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-48" ref-type="bibr">48</xref>, <xref rid="ref-49" ref-type="bibr">49</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-1204</td><td align="center" valign="top" rowspan="1" colspan="1">Wt</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;Cell Cycle Arrest,
<break/>&#x02191;Apoptosis</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-50" ref-type="bibr">50</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-130b</td><td align="center" valign="top" rowspan="1" colspan="1">Mut</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;EMT</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-53" ref-type="bibr">53</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-223</td><td align="center" valign="top" rowspan="1" colspan="1">Mut</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Chemoresistance</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-55" ref-type="bibr">55</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Let-7i</td><td align="center" valign="top" rowspan="1" colspan="1">Mut</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Migration/Invasion,
<break/>&#x02193;Metastasis</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-54" ref-type="bibr">54</xref>
</td></tr></tbody></table><table-wrap-foot><fn><p>*--Role not clear, or conflicting reports in different cancer types</p></fn></table-wrap-foot></table-wrap></sec><sec><title>p53 regulation by miRNA</title><p>The relationship between p53 and miRNAs is more complex than just transcription
regulation by p53. In fact, the interaction between the two is a two way street,
with several miRNAs being able to regulate p53 expression either through direct
targeting, or through regulation of other proteins that in turn modulate p53
expression and function. Some of the miRNAs regulated by p53 are actually able to
act in feedback loops to regulate p53 as well. We investigated the regulation
mechanism of p53 by miR-215 in colorectal cancer and discovered that a key target of
miR-215 is denticleless protein homolog (DTL). The suppression of DTL by miR-215
triggered an up-regulation of p53 and p21 <sup><xref rid="ref-26" ref-type="bibr">26</xref></sup>. DTL (RAMP, CDT2) is thought to play an essential role in DNA synthesis, cell
cycle progression, proliferation and differentiation <sup><xref rid="ref-56" ref-type="bibr">56</xref></sup>. DTL controls cell cycle progression through several different mechanisms,
and has an important role in the early radiation induced G2/M checkpoint <sup><xref rid="ref-57" ref-type="bibr">57</xref>, <xref rid="ref-58" ref-type="bibr">58</xref></sup>. The Proliferating cell nuclear antigen (PCNA)-coupled CUL4/DDB1/DTL complex
can ubiquitinate and degrade key cell cycle proteins such as p53, mouse double
minute 2 homolog (MDM2), p21, and E2F1 <sup><xref rid="ref-59" ref-type="bibr">59</xref>&#x02013; <xref rid="ref-61" ref-type="bibr">61</xref></sup>. miR-502, also regulated by p53, acts in a feedback loop to repress
expression of p53 indirectly <sup><xref rid="ref-24" ref-type="bibr">24</xref></sup>. miR-34 also acts in a feedback loop with p53 in colon cancer cells.
Transfection of miR-34 into colon cancer cells leads to an increase in p53 and p21
expression as a result of down regulation of the E2F pathway <sup><xref rid="ref-33" ref-type="bibr">33</xref></sup>. Several other miRNAs including miR-339-5p and miR-542-3p positively regulate
p53 through their targeting of p53 inhibitor MDM2 <sup><xref rid="ref-62" ref-type="bibr">62</xref>, <xref rid="ref-63" ref-type="bibr">63</xref></sup>. In addition to these miRNAs that regulate p53 through indirect mechanisms,
others have been found to directly target p53. Among the first miRNAs found to
target p53 directly, were miR-125b and miR-504 <sup><xref rid="ref-64" ref-type="bibr">64</xref>, <xref rid="ref-65" ref-type="bibr">65</xref></sup>. miR-504 was demonstrated to target p53 in several cancer types, and reduce
<italic>in vivo</italic> tumor growth of colon cancer cells <sup><xref rid="ref-65" ref-type="bibr">65</xref></sup>. In metastatic gastric cancer, miR-300 is up-regulated and acts as a tumor
promoter. miR-300 was found to directly target p53 by interacting with the 3'-UTR of
p53. Overexpression of miR-300 led to decreased p53 expression in gastric cancer
cells, and inhibition of miR-300 led to an increase in p53 expression.
Overexpression of p53 also reduced tumor promotion by miR-300, highlighting the
importance of p53 targeting in miR-300 cellular function <sup><xref rid="ref-66" ref-type="bibr">66</xref></sup>. Additionally, miR-25 and miR-30d directly targeted p53 to regulate apoptosis
in colon cancer cells <sup><xref rid="ref-67" ref-type="bibr">67</xref></sup>. These results suggest that not only can the functions of miRNAs be modulated
by the p53 status in colorectal cancer, the tumor suppressive function of p53 can
also be modulated by the post-transcriptional controls of various miRNAs under
different stress and/or physiological conditions, providing p53 with a greater
flexibility to control cell cycle and cell death.</p><p>Clearly miRNAs play important roles in the p53 regulatory network in GI cancer. p53
can regulate the transcription of several miRNAs that have important cellular
functions in GI cancer. In addition, several miRNAs can regulate p53 expression to
influence cellular pathways in cancer. The importance of the role of miRNAs in the
p53 network is reflected in several other reviews that highlight this interaction <sup><xref rid="ref-68" ref-type="bibr">68</xref>&#x02013; <xref rid="ref-72" ref-type="bibr">72</xref></sup>. Our understanding of these networks will likely continue to increase as we
expand our understanding of the important functions of miRNAs as well as the roles
of other non-coding RNAs in p53 regulation and function. <xref ref-type="table" rid="T2">Table 2</xref> summarizes some miRNAs that regulate p53 in GI cancers.
<xref ref-type="fig" rid="f1">Figure 1</xref> depicts the involvement of miRNAs
in the p53 regulatory network. </p><table-wrap id="T2" orientation="portrait" position="anchor"><label>Table 2. </label><caption><title>miRNAs that regulate p53 in GI Cancer.</title></caption><table frame="hsides" rules="groups" content-type="article-table"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1">miRNA</th><th align="center" valign="top" rowspan="1" colspan="1">Regulation +/-</th><th align="center" valign="top" rowspan="1" colspan="1">Direct/ <break/>Indirect</th><th align="center" valign="top" rowspan="1" colspan="1">Function</th><th align="center" valign="top" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-215</td><td align="center" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">Indirect</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;/&#x02193;Proliferation,
<break/>&#x02191;/&#x02193;Chemosensitivity, <break/>&#x02191;Cell Cycle Arrest</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-25" ref-type="bibr">25</xref>, <xref rid="ref-29" ref-type="bibr">29</xref>, <xref rid="ref-42" ref-type="bibr">42</xref>, <xref rid="ref-44" ref-type="bibr">44</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-502</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">Indirect</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Autophagy, &#x02191;Cell Cycle
<break/>Arrest</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-24" ref-type="bibr">24</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-34 </td><td align="center" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">Indirect</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Proliferation, &#x02191;Cell Cycle
<break/>Arrest, &#x02191;Apoptosis, <break/>&#x02191;Senescence, &#x02193;Tumor
<break/>Sphere Formation, &#x02193;EMT</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-9" ref-type="bibr">9</xref>, <xref rid="ref-28" ref-type="bibr">28</xref>, <xref rid="ref-110" ref-type="bibr">110</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-339-5p</td><td align="center" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">Indirect</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;Cell Cycle Arrest, <break/>&#x02191;Senescence,
&#x02193;Proliferation</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-62" ref-type="bibr">62</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-542-3p</td><td align="center" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">Indirect</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;Cell Cycle Arrest</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-63" ref-type="bibr">63</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-125b</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">Direct</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Apoptosis</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-64" ref-type="bibr">64</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-504</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">Direct</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Apoptosis, &#x02193;Cell Cycle
<break/>Arrest</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-65" ref-type="bibr">65</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-300</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">Direct</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;Proliferation, &#x02191;Migration</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-66" ref-type="bibr">66</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-25</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">Direct</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Apoptosis, &#x02193;Cell Cycle <break/>Arrest,
&#x02193;Senescence </td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-67" ref-type="bibr">67</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">miR-30d</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">Direct</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Apoptosis, &#x02193;Cell Cycle <break/>Arrest,
&#x02193;Senescence </td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-67" ref-type="bibr">67</xref>
</td></tr></tbody></table></table-wrap><fig fig-type="figure" id="f1" orientation="portrait" position="float"><label>Figure 1. </label><caption><title>miRNAs have important functions in the p53 regulatory network.</title><p>miRNAs regulate p53 through direct targeting as well through indirect
mechanisms such as targeting p53 regulators. p53 also regulates several
miRNAs, through transcriptional activation as well as other mechanisms. The
miRNAs involved in the p53 network carry out important functions regulating
several cellular pathways such as proliferation, apoptosis, invasion and
migration. In this figure, solid lines represent direct regulation, while
dashed lines represent indirect, or poorly characterized regulation.</p></caption><graphic xlink:href="f1000research-5-8996-g0000"/></fig></sec><sec><title>p53 and lncRNAs</title><p>Interaction between p53 and non-coding RNA is certainly not limited to miRNA. Recent
evidence has demonstrated that lncRNAs also have important functions in the p53
regulatory network. LncRNAs (200 nucleotides or more in length), thanks to
improvements in sequencing technology, have begun to emerge recently as critical
regulatory RNAs <sup><xref rid="ref-73" ref-type="bibr">73</xref>&#x02013; <xref rid="ref-75" ref-type="bibr">75</xref></sup>. The understanding of the roles of lncRNAs in diseases, such as cancer, is
still very limited but recent work has shown that these molecules can have some
important functions in cancer biology and like miRNA are tied into the p53
regulatory network.</p></sec><sec><title>LncRNAs regulated by p53</title><p>The field of lncRNA research remains in its early stages, and we are still
identifying more lncRNAs and discovering the important functions they have in the
cell. The progress that has been made thus far is quite interesting and encourages
increased investigation. A systematic ChIP-Seq analysis has identified 23 lncRNAs
that are up-regulated by p53 <sup><xref rid="ref-76" ref-type="bibr">76</xref></sup>. Among the over six thousand lncRNAs that have been identified, lincRNA-p21
is one of the better characterized lncRNAs and importantly, is regulated by p53 <sup><xref rid="ref-77" ref-type="bibr">77</xref>, <xref rid="ref-78" ref-type="bibr">78</xref></sup>. LincRNA-p21 locates next to the p21 gene on mouse chromosome 17 and is
activated upon DNA damaging signals in mouse cells. It has been reported that
lincRNA-p21 is a direct transcriptional target of p53 and is involved in
p53-dependent transcriptional responses. There is a significant overlap among the
genes regulated by lincRNA-p21 expression and genes that are repressed by p53.
Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) plays an important role in the
ability of lincRNA-p21 to regulate these genes. Expression of lincRNA-p21 in mouse
embryonic fibroblasts (MEFs) also has shown the ability to induce apoptosis <sup><xref rid="ref-77" ref-type="bibr">77</xref></sup>. Subsequent studies further revealed that lincRNA-p21 activates p21 in cis to
promote polycomb target gene expression and to enforce the G1/S checkpoint <sup><xref rid="ref-79" ref-type="bibr">79</xref></sup>. Recent studies also demonstrated that in human cervical carcinoma HeLa
cells, a RNA binding protein, human antigen R (HuR), modulates the expression level
of lincRNA-p21, which in turn regulates its target protein translation, such as
transcription factor jun-B (JUNB) and &#x003b2;-catenin <sup><xref rid="ref-78" ref-type="bibr">78</xref></sup>. Intriguingly for this review, lincRNA-p21 can be regulated by some miRNAs
including let-7 <sup><xref rid="ref-80" ref-type="bibr">80</xref></sup>. Our group has recently show that lincRNA-p21 is associated with colorectal
cancer progression <sup><xref rid="ref-81" ref-type="bibr">81</xref></sup>. Such association may be due to the unique function of lincRNA-p21 under
hypoxia. LincRNA-p21 is a hypoxia-responsive lncRNA and is essential for
hypoxia-enhanced glycolysis <sup><xref rid="ref-82" ref-type="bibr">82</xref></sup>. There is a positive feedback loop between hypoxia-inducible factor 1-alpha
(HIF-1&#x003b1;) and lincRNA-p21 to promote tumor growth and the regulation of the Warburg
effect. lincRNA-p21 has also been found to regulate the Wnt/&#x003b2;-catenin signaling
pathway, and be associated with susceptibility to radiation therapy in colon cancer <sup><xref rid="ref-83" ref-type="bibr">83</xref></sup>. LincRNA-p21 is a powerful example of a long non-coding RNA, regulated by p53
that carries out important functions in the response pathway of p53. Another p53
regulated lncRNA named, p53 induced noncoding transcript (Pint), is a direct
transcriptional target of p53. Pint is a nuclear RNA, that directly interacts with
polycomb repressive complex 2 (PRC2), and is required for PRC2 targeting of specific
genes for H3K27 tri-methylation and repression <sup><xref rid="ref-84" ref-type="bibr">84</xref></sup>. Pint is down-regulated in primary colon tumors and overexpression of Pint
inhibits tumor cell proliferation, suggesting a potential tumor suppressor role <sup><xref rid="ref-84" ref-type="bibr">84</xref></sup>. Tumor suppressor candidate 7 (Tusc7) (LncRNA loc285194) has also been shown
to be a p53 mediated tumor suppressor in colon cancer <sup><xref rid="ref-85" ref-type="bibr">85</xref></sup>. Tusc7 is transcriptionally activated by p53 to inhibit cell growth and
exerts its function by suppressing miR-211 <sup><xref rid="ref-85" ref-type="bibr">85</xref></sup>. In patient samples, Tusc7 was shown to be reduced in cancer compared to
normal colon tissue. Reduced Tusc7 expression is associated with increased tumor
size, stage and distant metastasis as well as decreased survival <sup><xref rid="ref-86" ref-type="bibr">86</xref></sup>. Similar results were found in esophageal cancer as well as pancreatic
cancer, suggesting Tusc7 might be a good biomarker candidate <sup><xref rid="ref-87" ref-type="bibr">87</xref>, <xref rid="ref-88" ref-type="bibr">88</xref></sup>. In gastric cancer, Tusc7 expression is reduced in patient samples, and in
cell lines decreases tumor cell growth. Tusc7 expression is also induced by wild
type p53 but not mutant p53 <sup><xref rid="ref-89" ref-type="bibr">89</xref></sup>. While Tusc7 seems to act as a tumor suppressor and is reduced in several
types of cancer, the picture for taurine up-regulated 1 (Tug1), another p53
regulated lncRNA, is not as clear. Tug1 was first discovered to be important in
retinal development and was then shown to be a direct transcriptional target of p53
in the context of non-small cell lung cancer <sup><xref rid="ref-90" ref-type="bibr">90</xref>, <xref rid="ref-91" ref-type="bibr">91</xref></sup>. The role of Tug1 in cancer however, seems to be different in different
cellular contexts. In lung cancer, Tug1 expression was found to be decreased in
cancer tissue compared to normal. Lower expression of Tug1 correlates with higher
tumor stage, increased tumor size and decreased overall survival <sup><xref rid="ref-91" ref-type="bibr">91</xref></sup>. In esophageal cancer however, the role of Tug1 seems to be quite different.
Tug1 is found to be over expressed in cancer tissue with expression being correlated
with tumor stage. Knockdown of Tug1 also seems to inhibit cancer cell proliferation
as well as migration <sup><xref rid="ref-92" ref-type="bibr">92</xref></sup>. This oncogenic type function for Tug1 has also been found in bladder cancer
where it appears to be up-regulated in cancer and promote cancer invasion as well as
resistance to radiotherapy <sup><xref rid="ref-93" ref-type="bibr">93</xref></sup>. There is clearly a need to perform more research on Tug1 to get a more
in-depth understanding of its functions, and confirm what has been found in these
different types of cancer. The disparity seen thus far however, may be due to
differences in functions of this lncRNA in different cellular contexts, something
that may be expected based on what we have already discovered about the functions of
miRNA in cancer. LncRNA activator of enhancer domains (LED) has recently been
identified via genome-wide profiling as a p53 induced lncRNAs that acts as an
enhancer to regulate p21 <sup><xref rid="ref-94" ref-type="bibr">94</xref></sup>. LED knockdown reduces p21 enhancer induction, activity, and cell cycle
arrest following p53 activation. LED was identified and its function assessed in
MCF-7 cells, however it has also been identified in a genome wide profile of colon
cancer cells, though its specific function in this cellular context will need to be
investigated <sup><xref rid="ref-95" ref-type="bibr">95</xref></sup>. Also identified in genome wide screening in colon cancer cells, PR-lncRNA-1
and PR-lncRNA-10 were identified as transcriptional targets of p53, that then act to
regulate the transcription of target genes. These lncRNAs, may have potential tumor
suppressor like function, and seem to play a role in regulating p53 anti-apoptotic
and cell cycle regulatory functions. They may be important lncRNAs to investigate
further <sup><xref rid="ref-96" ref-type="bibr">96</xref></sup>. Perhaps one of the more interesting p53 regulated lncRNAs is PVT1, which is
transcriptionally induced by p53. Evidence suggests that PVT1 has an anti-apoptotic
effect in colon cancer cells, and promotes proliferation and invasion <sup><xref rid="ref-50" ref-type="bibr">50</xref>, <xref rid="ref-97" ref-type="bibr">97</xref></sup>. PVT1 expression is also increased in colon cancer patients and increased
expression predicts poor prognosis. At the same time, miR-1204 is also encoded from
the PVT1 locus and seems to increase apoptosis and inhibit cell cycle progression <sup><xref rid="ref-50" ref-type="bibr">50</xref></sup>. This demonstrates the complex and dynamic nature of the relationship between
p53 and non-coding RNAs. Linc-Regulator Of Reprogramming (Linc-ROR) is a
transcriptional target of p53, and inhibits p53 related apoptosis and cell cycle
arrest <sup><xref rid="ref-98" ref-type="bibr">98</xref></sup>. Beyond GI cancers, PANDA has been identified as a lncRNA that is a direct
transcriptional target of p53. However, its function in GI cancers has not been
investigated. This is something that needs to be further investigated as PANDA may
have some roles in regulating apoptosis and cell cycle arrest in the p53 pathway <sup><xref rid="ref-99" ref-type="bibr">99</xref></sup>. <xref ref-type="table" rid="T3">Table 3</xref> summarizes the p53 regulated
lncRNAs based on their critical molecular and cellular functions in GI cancers.</p><table-wrap id="T3" orientation="portrait" position="anchor"><label>Table 3. </label><caption><title>p53 Regulated lncRNA in GI Cancer.</title></caption><table frame="hsides" rules="groups" content-type="article-table"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1">lncRNA</th><th align="center" valign="top" rowspan="1" colspan="1">Transcriptional <break/>Target</th><th align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor/ <break/>Oncogene</th><th align="center" valign="top" rowspan="1" colspan="1">Function</th><th align="center" valign="top" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">lincRNA-p21</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">*</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;Apoptosis, &#x02191;Cell <break/>Cycle Arrest,
<break/>&#x02191;Radiation <break/>Sensitivity, <break/>&#x02191;Hypoxia
Resistance</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-77" ref-type="bibr">77</xref>, <xref rid="ref-79" ref-type="bibr">79</xref>, <xref rid="ref-81" ref-type="bibr">81</xref>&#x02013; <xref rid="ref-83" ref-type="bibr">83</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Pint</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;Apoptosis, <break/>&#x02193;Proliferation</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-84" ref-type="bibr">84</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Tusc7</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor </td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Proliferation, </td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-85" ref-type="bibr">85</xref>&#x02013; <xref rid="ref-89" ref-type="bibr">89</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Tug1</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">*</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;Proliferation,
<break/>&#x02191;Migration/Invasion, <break/>&#x02191;EMT, &#x02191;Radiation
<break/>Resistance</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-91" ref-type="bibr">91</xref>&#x02013; <xref rid="ref-93" ref-type="bibr">93</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">LED</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">*</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;Cell Cycle Arrest</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-94" ref-type="bibr">94</xref>, <xref rid="ref-95" ref-type="bibr">95</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">PR-lncRNA-1</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;Apoptosis, <break/>&#x02193;Proliferation</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-96" ref-type="bibr">96</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">PR-lncRNA-10</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;Apoptosis, <break/>&#x02193;Proliferation</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-96" ref-type="bibr">96</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">PVT1</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">*</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;Proliferation <break/>&#x02193;Apoptosis</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-50" ref-type="bibr">50</xref>, <xref rid="ref-97" ref-type="bibr">97</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">LincRNA-ROR</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">*</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Apoptosis, <break/>&#x02193;Cell Cycle
Arrest</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-98" ref-type="bibr">98</xref>, <xref rid="ref-105" ref-type="bibr">105</xref>, <xref rid="ref-106" ref-type="bibr">106</xref>
</td></tr></tbody></table><table-wrap-foot><fn><p>*--Role not clear, or conflicting reports in different cancer types</p></fn></table-wrap-foot></table-wrap></sec><sec><title>p53 regulation by lncRNA</title><p>Clearly there are quite a few lncRNA that are regulated by p53 that are already known
to play important roles in cancer, and undoubtedly more will be discovered in the
near future. Like miRNAs however, the relationship between p53 and lncRNAs works
both ways, and there have been several lncRNAs discovered to regulate p53 as well.
LncRNAs can function as modulators by preventing p53 degradation. One example is
human maternally expressed gene 3 (MEG3). MEG3 is a non-coding RNA that functions as
a tumor suppressor in colon cancer cell lines. MEG3 down-regulates MDM2, which in
turn up-regulates p53 expression level <sup><xref rid="ref-100" ref-type="bibr">100</xref></sup>. MEG3 can inhibit cell proliferation in the absence of p53, suggesting a
possible p53 independent tumor suppressor role. LncRNAs can also inactivate p53
function and H19 is an example. The H19 lncRNA has been demonstrated to be
associated with p53 in gastric cancer <sup><xref rid="ref-101" ref-type="bibr">101</xref></sup>. Such interaction resulted in partial inactivation of p53. Metastasis
associated lung adenocarcinoma transcript 1 (MALAT-1) is another lncRNA that seems
to regulate p53. In the case of MALAT-1, it seems to be a negative regulator of p53,
and depletion of MALAT-1 leads to an increase in p53 expression <sup><xref rid="ref-102" ref-type="bibr">102</xref></sup>. In colon cancer, MALAT-1 has increased expression in cancer tissue vs.
normal. Increased MALAT-1 is associated with poor patient prognosis <sup><xref rid="ref-103" ref-type="bibr">103</xref></sup>. In colon cancer cell lines, overexpression of MALAT-1 promotes
proliferation, migration and invasion. These functions are associated with
regulation of A-kinase anchor protein 9 (AKAP-9) by MALAT-1 <sup><xref rid="ref-104" ref-type="bibr">104</xref></sup>. LincRNA-ROR acting in a feedback loop, is also able to regulate p53, and
knockdown of lincRNA-ROR leads to an increase in genes in the p53 pathway response <sup><xref rid="ref-98" ref-type="bibr">98</xref>, <xref rid="ref-105" ref-type="bibr">105</xref></sup>. There is also recent evidence that lincRNA-ROR expression is reduced in
colon cancer, however more needs to be done to investigate this role <sup><xref rid="ref-106" ref-type="bibr">106</xref></sup>. <xref ref-type="table" rid="T4">Table 4</xref> summarizes lncRNAs that
regulate p53 in GI cancers. Through their regulation by p53 or their ability to
regulate p53, lncRNAs clearly have important functions in the p53 network, and our
appreciation of these roles will continue to grow as we discover additional lncRNAs
and elucidate their functions in cancer. <xref ref-type="fig" rid="f2">Figure
2</xref> depicts lncRNAs&#x02019; roles in the p53 regulatory network.</p><table-wrap id="T4" orientation="portrait" position="anchor"><label>Table 4. </label><caption><title>lncRNA that regulate p53 in GI Cancer.</title></caption><table frame="hsides" rules="groups" content-type="article-table"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1">lncRNA</th><th align="center" valign="top" rowspan="1" colspan="1">Regulation +/-</th><th align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor/ <break/>Oncogene</th><th align="center" valign="top" rowspan="1" colspan="1">Function</th><th align="center" valign="top" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">MEG3</td><td align="center" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">Tumor Suppressor</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Proliferation</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-100" ref-type="bibr">100</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">H19</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">Oncogene</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;Proliferation, <break/>&#x02193;Apoptosis</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-101" ref-type="bibr">101</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">MALAT-1</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">Oncogene</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02191;Cell Cycle <break/>Progression,
<break/> &#x02191;Migration/Invasion</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-102" ref-type="bibr">102</xref>&#x02013; <xref rid="ref-104" ref-type="bibr">104</xref>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">LincRNA-ROR</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">*</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;Apoptosis, <break/>&#x02193;Cell Cycle
Arrest</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ref-98" ref-type="bibr">98</xref>, <xref rid="ref-105" ref-type="bibr">105</xref>, <xref rid="ref-106" ref-type="bibr">106</xref>
</td></tr></tbody></table><table-wrap-foot><fn><p>*--Role not clear, or conflicting reports in different cancer types</p></fn></table-wrap-foot></table-wrap><fig fig-type="figure" id="f2" orientation="portrait" position="float"><label>Figure 2. </label><caption><title>lncRNA have important functions in the p53 regulatory network.</title><p>lncRNAs, have a function in regulating p53. p53 in turn regulates the
expression of several different lncRNAs. The lncRNAs involved in the p53
network regulate cellular functions such as proliferation, apoptosis,
invasion and migration. In this figure, solid lines represent direct
regulation, while dashed lines represent indirect, or poorly characterized
regulation.</p></caption><graphic xlink:href="f1000research-5-8996-g0001"/></fig></sec><sec><title>Summary</title><p>The research community continues to push the boundaries of the p53 regulatory
networks beyond protein coding genes to non-coding RNAs and other novel entities.
There are many circular RNAs that have been discovered recently <sup><xref rid="ref-107" ref-type="bibr">107</xref>, <xref rid="ref-108" ref-type="bibr">108</xref></sup>. The impact of p53 on circular RNAs in GI cancer will potentially be an
important field to explore going forward. As protein coding genes only represent a
small percentage of our genome, we can expect more exciting discoveries in the
non-coding RNA field impacted by p53. We hope that with the advancement of high
throughput genomics technology and computational biology approaches, we can fully
access the complete spectrum and scope of the p53 regulatory network. Such insight
will provide a foundation to study other key proteins in cancer and other diseases.
It will also help us to develop novel therapeutic strategies to combat cancer <sup><xref rid="ref-109" ref-type="bibr">109</xref></sup>.</p></sec></body><back><ack><title>Acknowledgements</title><p>We apologize to our colleagues whose research was not cited in this review due to
space limitations and timing.</p></ack><ref-list><ref id="ref-1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kress</surname><given-names>M</given-names></name><name><surname>May</surname><given-names>E</given-names></name><name><surname>Cassingena</surname><given-names>R</given-names></name><etal/></person-group>: <article-title>Simian virus 40-transformed cells express new
species of proteins precipitable by anti-simian virus 40 tumor
serum.</article-title>
<source><italic>J Virol.</italic></source>
<year>1979</year>;<volume>31</volume>(<issue>2</issue>):<fpage>472</fpage>&#x02013;<lpage>483</lpage>.
<!--<pub-id pub-id-type="pmcid">353470</pub-id>-->
<pub-id pub-id-type="pmid">225566</pub-id></mixed-citation></ref><ref id="ref-2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lane</surname><given-names>DP</given-names></name><name><surname>Crawford</surname><given-names>LV</given-names></name></person-group>: <article-title>T antigen is bound to a host protein in
SV40-transformed cells.</article-title>
<source><italic>Nature.</italic></source>
<year>1979</year>;<volume>278</volume>(<issue>5701</issue>):<fpage>261</fpage>&#x02013;<lpage>263</lpage>.
<pub-id pub-id-type="doi">10.1038/278261a0</pub-id>
<pub-id pub-id-type="pmid">218111</pub-id></mixed-citation></ref><ref id="ref-3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Linzer</surname><given-names>DI</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name></person-group>: <article-title>Characterization of a 54K dalton cellular SV40
tumor antigen present in SV40-transformed cells and uninfected embryonal
carcinoma cells.</article-title>
<source><italic>Cell.</italic></source>
<year>1979</year>;<volume>17</volume>(<issue>1</issue>):<fpage>43</fpage>&#x02013;<lpage>52</lpage>.
<pub-id pub-id-type="doi">10.1016/0092-8674(79)90293-9</pub-id>
<pub-id pub-id-type="pmid">222475</pub-id></mixed-citation></ref><ref id="ref-4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group>: <article-title>p53 function and dysfunction.</article-title>
<source><italic>Cell.</italic></source>
<year>1992</year>;<volume>70</volume>(<issue>4</issue>):<fpage>523</fpage>&#x02013;<lpage>526</lpage>.
<pub-id pub-id-type="doi">10.1016/0092-8674(92)90421-8</pub-id>
<pub-id pub-id-type="pmid">1505019</pub-id></mixed-citation></ref><ref id="ref-5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riley</surname><given-names>T</given-names></name><name><surname>Sontag</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><etal/></person-group>: <article-title>Transcriptional control of human p53-regulated
genes.</article-title>
<source><italic>Nat Rev Mol Cell Biol.</italic></source>
<year>2008</year>;<volume>9</volume>(<issue>5</issue>):<fpage>402</fpage>&#x02013;<lpage>412</lpage>.
<pub-id pub-id-type="doi">10.1038/nrm2395</pub-id>
<pub-id pub-id-type="pmid">18431400</pub-id></mixed-citation></ref><ref id="ref-6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vaseva</surname><given-names>AV</given-names></name><name><surname>Moll</surname><given-names>UM</given-names></name></person-group>: <article-title>The mitochondrial p53 pathway.</article-title>
<source><italic>Biochim Biophys Acta.</italic></source>
<year>2009</year>;<volume>1787</volume>(<issue>5</issue>):<fpage>414</fpage>&#x02013;<lpage>420</lpage>.
<pub-id pub-id-type="doi">10.1016/j.bbabio.2008.10.005</pub-id>
<!--<pub-id pub-id-type="pmcid">2819081</pub-id>-->
<pub-id pub-id-type="pmid">19007744</pub-id></mixed-citation></ref><ref id="ref-7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mosner</surname><given-names>J</given-names></name><name><surname>Mummenbrauer</surname><given-names>T</given-names></name><name><surname>Bauer</surname><given-names>C</given-names></name><etal/></person-group>: <article-title>Negative feedback regulation of wild-type p53
biosynthesis.</article-title>
<source><italic>EMBO J.</italic></source>
<year>1995</year>;<volume>14</volume>(<issue>18</issue>):<fpage>4442</fpage>&#x02013;<lpage>4449</lpage>.
<!--<pub-id pub-id-type="pmcid">394536</pub-id>-->
<pub-id pub-id-type="pmid">7556087</pub-id></mixed-citation></ref><ref id="ref-8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xi</surname><given-names>Y</given-names></name><name><surname>Shalgi</surname><given-names>R</given-names></name><name><surname>Fodstad</surname><given-names>O</given-names></name><etal/></person-group>: <article-title>Differentially regulated micro-RNAs and actively
translated messenger RNA transcripts by tumor suppressor p53 in colon
cancer.</article-title>
<source><italic>Clin Cancer Res.</italic></source>
<year>2006</year>;<volume>12</volume>(<issue>7 Pt
1</issue>):<fpage>2014</fpage>&#x02013;<lpage>2024</lpage>.
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1853</pub-id>
<pub-id pub-id-type="pmid">16609010</pub-id></mixed-citation></ref><ref id="ref-9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raver-Shapira</surname><given-names>N</given-names></name><name><surname>Marciano</surname><given-names>E</given-names></name><name><surname>Meiri</surname><given-names>E</given-names></name><etal/></person-group>: <article-title>Transcriptional activation of miR-34a
contributes to p53-mediated apoptosis.</article-title>
<source><italic>Mol Cell.</italic></source>
<year>2007</year>;<volume>26</volume>(<issue>5</issue>):<fpage>731</fpage>&#x02013;<lpage>743</lpage>.
<pub-id pub-id-type="doi">10.1016/j.molcel.2007.05.017</pub-id>
<pub-id pub-id-type="pmid">17540598</pub-id></mixed-citation></ref><ref id="ref-10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ju</surname><given-names>J</given-names></name><name><surname>Pedersen-Lane</surname><given-names>J</given-names></name><name><surname>Maley</surname><given-names>F</given-names></name><etal/></person-group>: <article-title>Regulation of p53 expression by thymidylate
synthase.</article-title>
<source><italic>Proc Natl Acad Sci U S A.</italic></source>
<year>1999</year>;<volume>96</volume>(<issue>7</issue>):<fpage>3769</fpage>&#x02013;<lpage>3774</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.96.7.3769</pub-id>
<!--<pub-id pub-id-type="pmcid">22369</pub-id>-->
<pub-id pub-id-type="pmid">10097112</pub-id></mixed-citation></ref><ref id="ref-11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chu</surname><given-names>E</given-names></name><name><surname>Copur</surname><given-names>SM</given-names></name><name><surname>Ju</surname><given-names>J</given-names></name><etal/></person-group>: <article-title>Thymidylate synthase protein and p53 mRNA form
an <italic>in vivo</italic> ribonucleoprotein complex.</article-title>
<source><italic>Mol Cell Biol.</italic></source>
<year>1999</year>;<volume>19</volume>(<issue>2</issue>):<fpage>1582</fpage>&#x02013;<lpage>1594</lpage>.
<pub-id pub-id-type="doi">10.1128/MCB.19.2.1582</pub-id>
<!--<pub-id pub-id-type="pmcid">116086</pub-id>-->
<pub-id pub-id-type="pmid">9891091</pub-id></mixed-citation></ref><ref id="ref-12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garofalo</surname><given-names>M</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group>: <article-title>MicroRNAs as therapeutic targets in
chemoresistance.</article-title>
<source><italic>Drug Resist Updat.</italic></source>
<year>2013</year>;<volume>16</volume>(<issue>3&#x02013;5</issue>):<fpage>47</fpage>&#x02013;<lpage>59</lpage>.
<pub-id pub-id-type="doi">10.1016/j.drup.2013.05.001</pub-id>
<!--<pub-id pub-id-type="pmcid">3858390</pub-id>-->
<pub-id pub-id-type="pmid">23757365</pub-id></mixed-citation></ref><ref id="ref-13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mattick</surname><given-names>JS</given-names></name></person-group>: <article-title>The genetic signatures of noncoding
RNAs.</article-title>
<source><italic>PLoS Genet.</italic></source>
<year>2009</year>;<volume>5</volume>(<issue>4</issue>):<fpage>e1000459</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pgen.1000459</pub-id>
<!--<pub-id pub-id-type="pmcid">2667263</pub-id>-->
<pub-id pub-id-type="pmid">19390609</pub-id></mixed-citation></ref><ref id="ref-14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wahlestedt</surname><given-names>C</given-names></name></person-group>: <article-title>Targeting long non-coding RNA to therapeutically
upregulate gene expression.</article-title>
<source><italic>Nat Rev Drug Discov.</italic></source>
<year>2013</year>;<volume>12</volume>(<issue>6</issue>):<fpage>433</fpage>&#x02013;<lpage>446</lpage>.
<pub-id pub-id-type="doi">10.1038/nrd4018</pub-id>
<pub-id pub-id-type="pmid">23722346</pub-id></mixed-citation></ref><ref id="ref-15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gutschner</surname><given-names>T</given-names></name><name><surname>Diederichs</surname><given-names>S</given-names></name></person-group>: <article-title>The hallmarks of cancer: a long non-coding RNA
point of view.</article-title>
<source><italic>RNA Biol.</italic></source>
<year>2012</year>;<volume>9</volume>(<issue>6</issue>):<fpage>703</fpage>&#x02013;<lpage>719</lpage>.
<pub-id pub-id-type="doi">10.4161/rna.20481</pub-id>
<!--<pub-id pub-id-type="pmcid">3495743</pub-id>-->
<pub-id pub-id-type="pmid">22664915</pub-id></mixed-citation></ref><ref id="ref-16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scott</surname><given-names>N</given-names></name><name><surname>Sagar</surname><given-names>P</given-names></name><name><surname>Stewart</surname><given-names>J</given-names></name><etal/></person-group>: <article-title>p53 in colorectal cancer: clinicopathological
correlation and prognostic significance.</article-title>
<source><italic>Br J Cancer.</italic></source>
<year>1991</year>;<volume>63</volume>(<issue>2</issue>):<fpage>317</fpage>&#x02013;<lpage>319</lpage>.
<pub-id pub-id-type="doi">10.1038/bjc.1991.74</pub-id>
<!--<pub-id pub-id-type="pmcid">1971769</pub-id>-->
<pub-id pub-id-type="pmid">1997114</pub-id></mixed-citation></ref><ref id="ref-17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crawford</surname><given-names>LV</given-names></name><name><surname>Pim</surname><given-names>DC</given-names></name><name><surname>Lamb</surname><given-names>P</given-names></name></person-group>: <article-title>The cellular protein p53 in human
tumours.</article-title>
<source><italic>Mol Biol Med.</italic></source>
<year>1984</year>;<volume>2</volume>(<issue>4</issue>):<fpage>261</fpage>&#x02013;<lpage>272</lpage>.
<pub-id pub-id-type="pmid">6544917</pub-id></mixed-citation></ref><ref id="ref-18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Fearon</surname><given-names>ER</given-names></name><name><surname>Hamilton</surname><given-names>SR</given-names></name><etal/></person-group>: <article-title>Genetic alterations during colorectal-tumor
development.</article-title>
<source><italic>N Engl J Med.</italic></source>
<year>1988</year>;<volume>319</volume>(<issue>9</issue>):<fpage>525</fpage>&#x02013;<lpage>532</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJM198809013190901</pub-id>
<pub-id pub-id-type="pmid">2841597</pub-id></mixed-citation></ref><ref id="ref-19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Gish</surname><given-names>K</given-names></name><name><surname>Murphy</surname><given-names>M</given-names></name><etal/></person-group>: <article-title>Analysis of p53-regulated gene expression
patterns using oligonucleotide arrays.</article-title>
<source><italic>Genes Dev.</italic></source>
<year>2000</year>;<volume>14</volume>(<issue>8</issue>):<fpage>981</fpage>&#x02013;<lpage>993</lpage>.
<!--<pub-id pub-id-type="pmcid">316542</pub-id>-->
<pub-id pub-id-type="pmid">10783169</pub-id></mixed-citation></ref><ref id="ref-20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>SJ</given-names></name><name><surname>Suthiphongchai</surname><given-names>T</given-names></name><name><surname>Zambetti</surname><given-names>GP</given-names></name><etal/></person-group>: <article-title>p53 binds selectively to the 5' untranslated
region of <italic>cdk4</italic>, an RNA element necessary and sufficient for
transforming growth factor beta- and p53-mediated translational inhibition
of <italic>cdk4</italic>.</article-title>
<source><italic>Mol Cell Biol.</italic></source>
<year>2000</year>;<volume>20</volume>(<issue>22</issue>):<fpage>8420</fpage>&#x02013;<lpage>8431</lpage>.
<pub-id pub-id-type="doi">10.1128/MCB.20.22.8420-8431.2000</pub-id>
<!--<pub-id pub-id-type="pmcid">102149</pub-id>-->
<pub-id pub-id-type="pmid">11046139</pub-id></mixed-citation></ref><ref id="ref-21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>Benchimol</surname><given-names>S</given-names></name></person-group>: <article-title>Translational regulation of human p53 gene
expression.</article-title>
<source><italic>EMBO J.</italic></source>
<year>1996</year>;<volume>15</volume>(<issue>16</issue>):<fpage>4392</fpage>&#x02013;<lpage>4401</lpage>.
<!--<pub-id pub-id-type="pmcid">452163</pub-id>-->
<pub-id pub-id-type="pmid">8861966</pub-id></mixed-citation></ref><ref id="ref-22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group>: <article-title>MicroRNAs: genomics, biogenesis, mechanism, and
function.</article-title>
<source><italic>Cell.</italic></source>
<year>2004</year>;<volume>116</volume>(<issue>2</issue>):<fpage>281</fpage>&#x02013;<lpage>297</lpage>.
<pub-id pub-id-type="doi">10.1016/S0092-8674(04)00045-5</pub-id>
<pub-id pub-id-type="pmid">14744438</pub-id></mixed-citation></ref><ref id="ref-23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Friedman</surname><given-names>RC</given-names></name><name><surname>Farh</surname><given-names>KK</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><etal/></person-group>: <article-title>Most mammalian mRNAs are conserved targets of
microRNAs.</article-title>
<source><italic>Genome Res.</italic></source>
<year>2009</year>;<volume>19</volume>(<issue>1</issue>):<fpage>92</fpage>&#x02013;<lpage>105</lpage>.
<pub-id pub-id-type="doi">10.1101/gr.082701.108</pub-id>
<!--<pub-id pub-id-type="pmcid">2612969</pub-id>-->
<pub-id pub-id-type="pmid">18955434</pub-id></mixed-citation></ref><ref id="ref-24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhai</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><etal/></person-group>: <article-title>Inhibition of autophagy and tumor growth in
colon cancer by miR-502.</article-title>
<source><italic>Oncogene.</italic></source>
<year>2013</year>;<volume>32</volume>(<issue>12</issue>):<fpage>1570</fpage>&#x02013;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1038/onc.2012.167</pub-id>
<!--<pub-id pub-id-type="pmcid">3422411</pub-id>-->
<pub-id pub-id-type="pmid">22580605</pub-id></mixed-citation></ref><ref id="ref-25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Kudo</surname><given-names>K</given-names></name><etal/></person-group>: <article-title>
<italic>miR-192</italic> Regulates dihydrofolate reductase and cellular
proliferation through the p53-microRNA circuit.</article-title>
<source><italic>Clin Cancer Res.</italic></source>
<year>2008</year>;<volume>14</volume>(<issue>24</issue>):<fpage>8080</fpage>&#x02013;<lpage>8086</lpage>.
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-1422</pub-id>
<!--<pub-id pub-id-type="pmcid">2653201</pub-id>-->
<pub-id pub-id-type="pmid">19088023</pub-id></mixed-citation></ref><ref id="ref-26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Titmus</surname><given-names>MA</given-names></name><etal/></person-group>: <article-title>Molecular mechanism of chemoresistance by
miR-215 in osteosarcoma and colon cancer cells.</article-title>
<source><italic>Mol Cancer.</italic></source>
<year>2010</year>;<volume>9</volume>:<fpage>96</fpage>.
<pub-id pub-id-type="doi">10.1186/1476-4598-9-96</pub-id>
<!--<pub-id pub-id-type="pmcid">2881118</pub-id>-->
<pub-id pub-id-type="pmid">20433742</pub-id></mixed-citation></ref><ref id="ref-27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xi</surname><given-names>Y</given-names></name><etal/></person-group>: <article-title>Mechanism of chemoresistance mediated by miR-140
in human osteosarcoma and colon cancer cells.</article-title>
<source><italic>Oncogene.</italic></source>
<year>2009</year>;<volume>28</volume>(<issue>46</issue>):<fpage>4065</fpage>&#x02013;<lpage>4074</lpage>.
<pub-id pub-id-type="doi">10.1038/onc.2009.274</pub-id>
<!--<pub-id pub-id-type="pmcid">2783211</pub-id>-->
<pub-id pub-id-type="pmid">19734943</pub-id></mixed-citation></ref><ref id="ref-28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>TC</given-names></name><name><surname>Wentzel</surname><given-names>EA</given-names></name><name><surname>Kent</surname><given-names>OA</given-names></name><etal/></person-group>: <article-title>Transactivation of miR-34a by p53 broadly
influences gene expression and promotes apoptosis.</article-title>
<source><italic>Mol Cell.</italic></source>
<year>2007</year>;<volume>26</volume>(<issue>5</issue>):<fpage>745</fpage>&#x02013;<lpage>752</lpage>.
<pub-id pub-id-type="doi">10.1016/j.molcel.2007.05.010</pub-id>
<!--<pub-id pub-id-type="pmcid">1939978</pub-id>-->
<pub-id pub-id-type="pmid">17540599</pub-id></mixed-citation></ref><ref id="ref-29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braun</surname><given-names>CJ</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Savelyeva</surname><given-names>I</given-names></name><etal/></person-group>: <article-title>p53-Responsive micrornas 192 and 215 are capable
of inducing cell cycle arrest.</article-title>
<source><italic>Cancer Res.</italic></source>
<year>2008</year>;<volume>68</volume>(<issue>24</issue>):<fpage>10094</fpage>&#x02013;<lpage>10104</lpage>.
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-1569</pub-id>
<!--<pub-id pub-id-type="pmcid">2836584</pub-id>-->
<pub-id pub-id-type="pmid">19074875</pub-id></mixed-citation></ref><ref id="ref-30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gregory</surname><given-names>PA</given-names></name><name><surname>Bert</surname><given-names>AG</given-names></name><name><surname>Paterson</surname><given-names>EL</given-names></name><etal/></person-group>: <article-title>The miR-200 family and miR-205 regulate
epithelial to mesenchymal transition by targeting ZEB1 and
SIP1.</article-title>
<source><italic>Nat Cell Biol.</italic></source>
<year>2008</year>;<volume>10</volume>(<issue>5</issue>):<fpage>593</fpage>&#x02013;<lpage>601</lpage>.
<pub-id pub-id-type="doi">10.1038/ncb1722</pub-id>
<pub-id pub-id-type="pmid">18376396</pub-id></mixed-citation></ref><ref id="ref-31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeitels</surname><given-names>LR</given-names></name><name><surname>Acharya</surname><given-names>A</given-names></name><name><surname>Shi </surname><given-names>G</given-names></name><etal/></person-group>: <article-title>Tumor suppression by miR-26 overrides potential
oncogenic activity in intestinal tumorigenesis.</article-title>
<source><italic>Genes Dev.</italic></source>
<year>2014</year>;<volume>28</volume>(<issue>23</issue>):<fpage>2585</fpage>&#x02013;<lpage>2590</lpage>.
<pub-id pub-id-type="doi">10.1101/gad.250951.114</pub-id>
<!--<pub-id pub-id-type="pmcid">4248289</pub-id>-->
<pub-id pub-id-type="pmid">25395662</pub-id></mixed-citation></ref><ref id="ref-32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deng</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>HL</given-names></name><name><surname>Lu</surname><given-names>XH</given-names></name><etal/></person-group>: <article-title>miR-26a suppresses tumor growth and metastasis
by targeting FGF9 in gastric cancer.</article-title>
<source><italic>PLoS One.</italic></source>
<year>2013</year>;<volume>8</volume>(<issue>8</issue>):<fpage>e72662</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0072662</pub-id>
<!--<pub-id pub-id-type="pmcid">3756000</pub-id>-->
<pub-id pub-id-type="pmid">24015269</pub-id></mixed-citation></ref><ref id="ref-33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tazawa</surname><given-names>H</given-names></name><name><surname>Tsuchiya</surname><given-names>N</given-names></name><name><surname>Izumiya</surname><given-names>M</given-names></name><etal/></person-group>: <article-title>Tumor-suppressive <italic>miR-34a</italic>
induces senescence-like growth arrest through modulation of the E2F pathway
in human colon cancer cells.</article-title>
<source><italic>Proc Natl Acad Sci U S A.</italic></source>
<year>2007</year>;<volume>104</volume>(<issue>39</issue>):<fpage>15472</fpage>&#x02013;<lpage>15477</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.0707351104</pub-id>
<!--<pub-id pub-id-type="pmcid">2000550</pub-id>-->
<pub-id pub-id-type="pmid">17875987</pub-id></mixed-citation></ref><ref id="ref-34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>He</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Lim</surname><given-names>LP</given-names></name><etal/></person-group>: <article-title>A microRNA component of the p53 tumour
suppressor network.</article-title>
<source><italic>Nature.</italic></source>
<year>2007</year>;<volume>447</volume>(<issue>7148</issue>):<fpage>1130</fpage>&#x02013;<lpage>1134</lpage>.
<pub-id pub-id-type="doi">10.1038/nature05939</pub-id>
<!--<pub-id pub-id-type="pmcid">4590999</pub-id>-->
<pub-id pub-id-type="pmid">17554337</pub-id></mixed-citation></ref><ref id="ref-35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yamakuchi</surname><given-names>M</given-names></name><name><surname>Ferlito</surname><given-names>M</given-names></name><name><surname>Lowenstein</surname><given-names>CJ</given-names></name></person-group>: <article-title>miR-34a repression of SIRT1 regulates
apoptosis.</article-title>
<source><italic>Proc Natl Acad Sci U S A.</italic></source>
<year>2008</year>;<volume>105</volume>(<issue>36</issue>):<fpage>13421</fpage>&#x02013;<lpage>13426</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.0801613105</pub-id>
<!--<pub-id pub-id-type="pmcid">2533205</pub-id>-->
<pub-id pub-id-type="pmid">18755897</pub-id></mixed-citation></ref><ref id="ref-36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rokavec</surname><given-names>M</given-names></name><name><surname>&#x000d6;ner</surname><given-names>MG</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group>: <article-title>IL-6R/STAT3/miR-34a feedback loop promotes
EMT-mediated colorectal cancer invasion and metastasis.</article-title>
<source><italic>J Clin Invest.</italic></source>
<year>2014</year>;<volume>124</volume>(<issue>4</issue>):<fpage>1853</fpage>&#x02013;<lpage>1867</lpage>.
<pub-id pub-id-type="doi">10.1172/JCI73531</pub-id>
<!--<pub-id pub-id-type="pmcid">3973098</pub-id>-->
<pub-id pub-id-type="pmid">24642471</pub-id></mixed-citation></ref><ref id="ref-37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hermeking</surname><given-names>H</given-names></name></person-group>: <article-title>The <italic>miR-34</italic> family in cancer and
apoptosis.</article-title>
<source><italic>Cell Death Differ.</italic></source>
<year>2010</year>;<volume>17</volume>(<issue>2</issue>):<fpage>193</fpage>&#x02013;<lpage>199</lpage>.
<pub-id pub-id-type="doi">10.1038/cdd.2009.56</pub-id>
<pub-id pub-id-type="pmid">19461653</pub-id></mixed-citation></ref><ref id="ref-38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ji</surname><given-names>Q</given-names></name><name><surname>Hao</surname><given-names>X</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><etal/></person-group>: <article-title>Restoration of tumor suppressor miR-34 inhibits
human p53-mutant gastric cancer tumorspheres.</article-title>
<source><italic>BMC Cancer.</italic></source>
<year>2008</year>;<volume>8</volume>:<fpage>266</fpage>.
<pub-id pub-id-type="doi">10.1186/1471-2407-8-266</pub-id>
<!--<pub-id pub-id-type="pmcid">2564978</pub-id>-->
<pub-id pub-id-type="pmid">18803879</pub-id></mixed-citation></ref><ref id="ref-39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bader</surname><given-names>AG</given-names></name></person-group>: <article-title>miR-34 - a microRNA replacement therapy is
headed to the clinic.</article-title>
<source><italic>Front Genet.</italic></source>
<year>2012</year>;<volume>3</volume>:<fpage>120</fpage>.
<pub-id pub-id-type="doi">10.3389/fgene.2012.00120</pub-id>
<!--<pub-id pub-id-type="pmcid">3387671</pub-id>-->
<pub-id pub-id-type="pmid">22783274</pub-id></mixed-citation></ref><ref id="ref-40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Georges</surname><given-names>SA</given-names></name><name><surname>Biery</surname><given-names>MC</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><etal/></person-group>: <article-title>Coordinated regulation of cell cycle transcripts
by p53-Inducible microRNAs, miR-192 and miR-215.</article-title>
<source><italic>Cancer Res.</italic></source>
<year>2008</year>;<volume>68</volume>(<issue>24</issue>):<fpage>10105</fpage>&#x02013;<lpage>10112</lpage>.
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-1846</pub-id>
<pub-id pub-id-type="pmid">19074876</pub-id></mixed-citation></ref><ref id="ref-41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karaayvaz</surname><given-names>M</given-names></name><name><surname>Pal</surname><given-names>T</given-names></name><name><surname>Song</surname><given-names>B</given-names></name><etal/></person-group>: <article-title>Prognostic significance of miR-215 in colon
cancer.</article-title>
<source><italic>Clin Colorectal Cancer.</italic></source>
<year>2011</year>.<volume>10</volume>(<issue>4</issue>):<fpage>340</fpage>&#x02013;<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1016/j.clcc.2011.06.002</pub-id>
<!--<pub-id pub-id-type="pmcid">3390153</pub-id>-->
<pub-id pub-id-type="pmid">21752725</pub-id></mixed-citation></ref><ref id="ref-42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boni</surname><given-names>V</given-names></name><name><surname>Bitarte</surname><given-names>N</given-names></name><name><surname>Cristobal</surname><given-names> I</given-names></name><etal/></person-group>: <article-title>miR-192/miR-215 influence 5-fluorouracil
resistance through cell cycle-mediated mechanisms complementary to its
post-transcriptional thymidilate synthase regulation.</article-title>
<source><italic>Mol Cancer Ther.</italic></source>
<year>2010</year>;<volume>9</volume>(<issue>8</issue>):<fpage>2265</fpage>&#x02013;<lpage>2275</lpage>.
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-10-0061</pub-id>
<pub-id pub-id-type="pmid">20647341</pub-id></mixed-citation></ref><ref id="ref-43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><etal/></person-group>: <article-title>MiR-215 modulates gastric cancer cell
proliferation by targeting RB1.</article-title>
<source><italic>Cancer Lett.</italic></source>
<year>2014</year>;<volume>342</volume>(<issue>1</issue>):<fpage>27</fpage>&#x02013;<lpage>35</lpage>.
<pub-id pub-id-type="doi">10.1016/j.canlet.2013.08.033</pub-id>
<pub-id pub-id-type="pmid">23981575</pub-id></mixed-citation></ref><ref id="ref-44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>YJ</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name></person-group>: <article-title>MiR-215/192 participates in gastric cancer
progression.</article-title>
<source><italic>Clin Transl Oncol.</italic></source>
<year>2015</year>;<volume>17</volume>(<issue>1</issue>):<fpage>34</fpage>&#x02013;<lpage>40</lpage>.
<pub-id pub-id-type="doi">10.1007/s12094-014-1194-6</pub-id>
<pub-id pub-id-type="pmid">24981590</pub-id></mixed-citation></ref><ref id="ref-45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bansal</surname><given-names>A</given-names></name><name><surname>Hong</surname><given-names> X</given-names></name><name><surname>Lee</surname><given-names>IH</given-names></name><etal/></person-group>: <article-title>MicroRNA Expression can be a Promising Strategy
for the Detection of Barrett's Esophagus: A Pilot Study.</article-title>
<source><italic>Clin Transl Gastroenterol.</italic></source>
<year>2014</year>;<volume>5</volume>(<issue>12</issue>):<fpage>e65</fpage>.
<pub-id pub-id-type="doi">10.1038/ctg.2014.17</pub-id>
<!--<pub-id pub-id-type="pmcid">4274369</pub-id>-->
<pub-id pub-id-type="pmid">25502391</pub-id></mixed-citation></ref><ref id="ref-46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sundaram</surname><given-names>P</given-names></name><name><surname>Hultine</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>LM</given-names></name><etal/></person-group>: <article-title>p53-responsive miR-194 inhibits thrombospondin-1
and promotes angiogenesis in colon cancers.</article-title>
<source><italic>Cancer Res.</italic></source>
<year>2011</year>;<volume>71</volume>(<issue>24</issue>):<fpage>7490</fpage>&#x02013;<lpage>7501</lpage>.
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1124</pub-id>
<!--<pub-id pub-id-type="pmcid">3242824</pub-id>-->
<pub-id pub-id-type="pmid">22028325</pub-id></mixed-citation></ref><ref id="ref-47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zang</surname><given-names>W</given-names></name><etal/></person-group>: <article-title>miR-194 targets RBX1 gene to modulate
proliferation and migration of gastric cancer cells.</article-title>
<source><italic>Tumour Biol.</italic></source>
<year>2015</year>;<volume>36</volume>(<issue>4</issue>):<fpage>2393</fpage>&#x02013;<lpage>2401</lpage>.
<pub-id pub-id-type="doi">10.1007/s13277-014-2849-1</pub-id>
<pub-id pub-id-type="pmid">25412959</pub-id></mixed-citation></ref><ref id="ref-48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sachdeva</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><etal/></person-group>: <article-title>p53 represses c-Myc through induction of the
tumor suppressor <italic>miR-145</italic>.</article-title>
<source><italic>Proc Natl Acad Sci U S A.</italic></source>
<year>2009</year>;<volume>106</volume>(<issue>9</issue>):<fpage>3207</fpage>&#x02013;<lpage>3212</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.0808042106</pub-id>
<!--<pub-id pub-id-type="pmcid">2651330</pub-id>-->
<pub-id pub-id-type="pmid">19202062</pub-id></mixed-citation></ref><ref id="ref-49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>HI</given-names></name><name><surname>Yamagata</surname><given-names>K</given-names></name><name><surname>Sugimoto</surname><given-names>K</given-names></name><etal/></person-group>: <article-title>Modulation of microRNA processing by
p53.</article-title>
<source><italic>Nature.</italic></source>
<year>2009</year>;<volume>460</volume>(<issue>7254</issue>):<fpage>529</fpage>&#x02013;<lpage>33</lpage>.
<pub-id pub-id-type="doi">10.1038/nature08199</pub-id>
<pub-id pub-id-type="pmid">19626115</pub-id></mixed-citation></ref><ref id="ref-50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barsotti</surname><given-names>AM</given-names></name><name><surname>Beckerman</surname><given-names>R</given-names></name><name><surname>Laptenko</surname><given-names>O</given-names></name><etal/></person-group>: <article-title>p53-Dependent induction of <italic>PVT1</italic>
and miR-1204.</article-title>
<source><italic>J Biol Chem.</italic></source>
<year>2012</year>;<volume>287</volume>(<issue>4</issue>):<fpage>2509</fpage>&#x02013;<lpage>2519</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M111.322875</pub-id>
<!--<pub-id pub-id-type="pmcid">3268411</pub-id>-->
<pub-id pub-id-type="pmid">22110125</pub-id></mixed-citation></ref><ref id="ref-51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dittmer</surname><given-names>D</given-names></name><name><surname>Pati</surname><given-names>S</given-names></name><name><surname>Zambetti</surname><given-names>G</given-names></name><etal/></person-group>: <article-title>Gain of function mutations in
p53.</article-title>
<source><italic>Nat Genet.</italic></source>
<year>1993</year>;<volume>4</volume>(<issue>1</issue>):<fpage>42</fpage>&#x02013;<lpage>46</lpage>.
<pub-id pub-id-type="doi">10.1038/ng0593-42</pub-id>
<pub-id pub-id-type="pmid">8099841</pub-id></mixed-citation></ref><ref id="ref-52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blandino</surname><given-names>G</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name><name><surname>Oren</surname><given-names>M</given-names></name></person-group>: <article-title>Mutant p53 gain of function: differential
effects of different p53 mutants on resistance of cultured cells to
chemotherapy.</article-title>
<source><italic>Oncogene.</italic></source>
<year>1999</year>;<volume>18</volume>(<issue>2</issue>):<fpage>477</fpage>&#x02013;<lpage>485</lpage>.
<pub-id pub-id-type="pmid">9927204</pub-id></mixed-citation></ref><ref id="ref-53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dong</surname><given-names>P</given-names></name><name><surname>Karaayvaz</surname><given-names>M</given-names></name><name><surname>Jia</surname><given-names>N</given-names></name><etal/></person-group>: <article-title>Mutant p53 gain-of-function induces
epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1
axis.</article-title>
<source><italic>Oncogene.</italic></source>
<year>2013</year>;<volume>32</volume>(<issue>27</issue>):<fpage>3286</fpage>&#x02013;<lpage>3295</lpage>.
<pub-id pub-id-type="doi">10.1038/onc.2012.334</pub-id>
<!--<pub-id pub-id-type="pmcid">3705163</pub-id>-->
<pub-id pub-id-type="pmid">22847613</pub-id></mixed-citation></ref><ref id="ref-54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>M</given-names></name><name><surname>Francis</surname><given-names>P</given-names></name><name><surname>Bilke</surname><given-names>S</given-names></name><etal/></person-group>: <article-title>A mutant p53/let-7i-axis-regulated gene network
drives cell migration, invasion and metastasis.</article-title>
<source><italic>Oncogene.</italic></source>
<year>2015</year>;<volume>34</volume>(<issue>9</issue>):<fpage>1094</fpage>&#x02013;<lpage>1104</lpage>.
<pub-id pub-id-type="doi">10.1038/onc.2014.46</pub-id>
<!--<pub-id pub-id-type="pmcid">4391367</pub-id>-->
<pub-id pub-id-type="pmid">24662829</pub-id></mixed-citation></ref><ref id="ref-55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Masciarelli</surname><given-names>S</given-names></name><name><surname>Fontemaggi</surname><given-names>G</given-names></name><name><surname>Di Agostino</surname><given-names>S</given-names></name><etal/></person-group>: <article-title>Gain-of-function mutant p53 downregulates
miR-223 contributing to chemoresistance of cultured tumor
cells.</article-title>
<source><italic>Oncogene.</italic></source>
<year>2014</year>;<volume>33</volume>(<issue>12</issue>):<fpage>1601</fpage>&#x02013;<lpage>1608</lpage>.
<pub-id pub-id-type="doi">10.1038/onc.2013.106</pub-id>
<pub-id pub-id-type="pmid">23584479</pub-id></mixed-citation></ref><ref id="ref-56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pan</surname><given-names>HW</given-names></name><name><surname>Chou</surname><given-names>HY</given-names></name><name><surname>Liu</surname><given-names>SH</given-names></name><etal/></person-group>: <article-title>Role of L2DTL, cell cycle-regulated nuclear and
centrosome protein, in aggressive hepatocellular carcinoma.</article-title>
<source><italic>Cell cycle.</italic></source>
<year>2006</year>;<volume>5</volume>(<issue>22</issue>):<fpage>2676</fpage>&#x02013;<lpage>2687</lpage>.
<pub-id pub-id-type="doi">10.4161/cc.5.22.3500</pub-id>
<pub-id pub-id-type="pmid">17106265</pub-id></mixed-citation></ref><ref id="ref-57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Higa</surname><given-names>LA</given-names></name><name><surname>Banks</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><etal/></person-group>: <article-title>L2DTL/CDT2 interacts with the CUL4/DDB1 complex
and PCNA and regulates CDT1 proteolysis in response to DNA
damage.</article-title>
<source><italic>Cell cycle.</italic></source>
<year>2006</year>;<volume>5</volume>(<issue>15</issue>):<fpage>1675</fpage>&#x02013;<lpage>1680</lpage>.
<pub-id pub-id-type="doi">10.4161/cc.5.15.3149</pub-id>
<pub-id pub-id-type="pmid">16861906</pub-id></mixed-citation></ref><ref id="ref-58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sansam</surname><given-names>CL</given-names></name><name><surname>Shepard</surname><given-names>JL</given-names></name><name><surname>Lai</surname><given-names>K</given-names></name><etal/></person-group>: <article-title>DTL/CDT2 is essential for both CDT1 regulation
and the early G2/M checkpoint.</article-title>
<source><italic>Genes Dev.</italic></source>
<year>2006</year>;<volume>20</volume>(<issue>22</issue>):<fpage>3117</fpage>&#x02013;<lpage>3129</lpage>.
<pub-id pub-id-type="doi">10.1101/gad.1482106</pub-id>
<!--<pub-id pub-id-type="pmcid">1635147</pub-id>-->
<pub-id pub-id-type="pmid">17085480</pub-id></mixed-citation></ref><ref id="ref-59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Banks</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Higa</surname><given-names>LA</given-names></name><etal/></person-group>: <article-title>L2DTL/CDT2 and PCNA interact with p53 and
regulate p53 polyubiquitination and protein stability through MDM2 and
CUL4A/DDB1 complexes.</article-title>
<source><italic>Cell cycle.</italic></source>
<year>2006</year>;<volume>5</volume>(<issue>15</issue>):<fpage>1719</fpage>&#x02013;<lpage>1729</lpage>.
<pub-id pub-id-type="doi">10.4161/cc.5.15.3150</pub-id>
<pub-id pub-id-type="pmid">16861890</pub-id></mixed-citation></ref><ref id="ref-60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nishitani</surname><given-names>H</given-names></name><name><surname>Shiomi</surname><given-names>Y</given-names></name><name><surname>Iida</surname><given-names>H</given-names></name><etal/></person-group>: <article-title>CDK inhibitor p21 is degraded by a proliferating
cell nuclear antigen-coupled Cul4-DDB1 <sup>Cdt2</sup> pathway during S
phase and after UV irradiation.</article-title>
<source><italic>J Biol Chem.</italic></source>
<year>2008</year>;<volume>283</volume>(<issue>43</issue>):<fpage>29045</fpage>&#x02013;<lpage>29052</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M806045200</pub-id>
<!--<pub-id pub-id-type="pmcid">2662008</pub-id>-->
<pub-id pub-id-type="pmid">18703516</pub-id></mixed-citation></ref><ref id="ref-61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shibutani</surname><given-names>ST</given-names></name><name><surname>de la Cruz</surname><given-names>AF</given-names></name><name><surname>Tran</surname><given-names>V</given-names></name><etal/></person-group>: <article-title>Intrinsic negative cell cycle regulation
provided by PIP box- and Cul4 <sup>Cdt2</sup>-mediated destruction of E2f1
during S phase.</article-title>
<source><italic>Dev Cell.</italic></source>
<year>2008</year>;<volume>15</volume>(<issue>6</issue>):<fpage>890</fpage>&#x02013;<lpage>900</lpage>.
<pub-id pub-id-type="doi">10.1016/j.devcel.2008.10.003</pub-id>
<!--<pub-id pub-id-type="pmcid">2644461</pub-id>-->
<pub-id pub-id-type="pmid">19081076</pub-id></mixed-citation></ref><ref id="ref-62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jansson</surname><given-names>MD</given-names></name><name><surname>Damas</surname><given-names>ND</given-names></name><name><surname>Lees</surname><given-names>M</given-names></name><etal/></person-group>: <article-title>miR-339-5p regulates the p53 tumor-suppressor
pathway by targeting MDM2.</article-title>
<source><italic>Oncogene.</italic></source>
<year>2015</year>;<volume>34</volume>(<issue>15</issue>):<fpage>1908</fpage>&#x02013;<lpage>1918</lpage>.
<pub-id pub-id-type="doi">10.1038/onc.2014.130</pub-id>
<pub-id pub-id-type="pmid">24882579</pub-id></mixed-citation></ref><ref id="ref-63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>JW</given-names></name><name><surname>Castella</surname><given-names>M</given-names></name><etal/></person-group>: <article-title>p53 is positively regulated by
miR-542-3p.</article-title>
<source><italic>Cancer Res.</italic></source>
<year>2014</year>;<volume>74</volume>(<issue>12</issue>):<fpage>3218</fpage>&#x02013;<lpage>3227</lpage>.
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1706</pub-id>
<!--<pub-id pub-id-type="pmcid">4058365</pub-id>-->
<pub-id pub-id-type="pmid">24762395</pub-id></mixed-citation></ref><ref id="ref-64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Le</surname><given-names>MT</given-names></name><name><surname>Teh</surname><given-names>C</given-names></name><name><surname>Shyh-Chang</surname><given-names>N</given-names></name><etal/></person-group>: <article-title>MicroRNA-125b is a novel negative regulator of
p53.</article-title>
<source><italic>Genes Dev.</italic></source>
<year>2009</year>;<volume>23</volume>(<issue>7</issue>):<fpage>862</fpage>&#x02013;<lpage>876</lpage>.
<pub-id pub-id-type="doi">10.1101/gad.1767609</pub-id>
<!--<pub-id pub-id-type="pmcid">2666337</pub-id>-->
<pub-id pub-id-type="pmid">19293287</pub-id></mixed-citation></ref><ref id="ref-65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Chan</surname><given-names>CS</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><etal/></person-group>: <article-title>Negative regulation of tumor suppressor p53 by
microRNA miR-504.</article-title>
<source><italic>Mol Cell.</italic></source>
<year>2010</year>;<volume>38</volume>(<issue>5</issue>):<fpage>689</fpage>&#x02013;<lpage>699</lpage>.
<pub-id pub-id-type="doi">10.1016/j.molcel.2010.05.027</pub-id>
<!--<pub-id pub-id-type="pmcid">2900922</pub-id>-->
<pub-id pub-id-type="pmid">20542001</pub-id></mixed-citation></ref><ref id="ref-66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><etal/></person-group>: <article-title>The up-regulation of miR-300 in gastric cancer
and its effects on cells malignancy.</article-title>
<source><italic>Int J Clin Exp Med.</italic></source>
<year>2015</year>;<volume>8</volume>(<issue>5</issue>):<fpage>6773</fpage>&#x02013;<lpage>6783</lpage>.
<!--<pub-id pub-id-type="pmcid">4509160</pub-id>-->
<pub-id pub-id-type="pmid">26221215</pub-id></mixed-citation></ref><ref id="ref-67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Takwi</surname><given-names>AA</given-names></name><etal/></person-group>: <article-title>Negative regulation of the tumor suppressor
<italic>p53</italic> gene by microRNAs.</article-title>
<source><italic>Oncogene.</italic></source>
<year>2011</year>;<volume>30</volume>(<issue>7</issue>):<fpage>843</fpage>&#x02013;<lpage>853</lpage>.
<pub-id pub-id-type="doi">10.1038/onc.2010.457</pub-id>
<!--<pub-id pub-id-type="pmcid">3021102</pub-id>-->
<pub-id pub-id-type="pmid">20935678</pub-id></mixed-citation></ref><ref id="ref-68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Otsuka</surname><given-names>K</given-names></name><name><surname>Ochiya</surname><given-names>T</given-names></name></person-group>: <article-title>Genetic networks lead and follow tumor
development: microRNA regulation of cell cycle and apoptosis in the p53
pathways.</article-title>
<source><italic>Biomed Res Int.</italic></source>
<year>2014</year>;<volume>2014</volume>: 749724.
<pub-id pub-id-type="doi">10.1155/2014/749724</pub-id>
<!--<pub-id pub-id-type="pmcid">4180389</pub-id>-->
<pub-id pub-id-type="pmid">25302307</pub-id></mixed-citation></ref><ref id="ref-69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rokavec</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><etal/></person-group>: <article-title>The p53/microRNA connection in gastrointestinal
cancer.</article-title>
<source><italic>Clin Exp Gastroenterol.</italic></source>
<year>2014</year>;<volume>7</volume>:<fpage>395</fpage>&#x02013;<lpage>413</lpage>.
<pub-id pub-id-type="doi">10.2147/CEG.S43738</pub-id>
<!--<pub-id pub-id-type="pmcid">4198153</pub-id>-->
<pub-id pub-id-type="pmid">25328413</pub-id></mixed-citation></ref><ref id="ref-70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>Y</given-names></name><name><surname>Pilpel</surname><given-names>Y</given-names></name><name><surname>Oren</surname><given-names>M</given-names></name></person-group>: <article-title>microRNAs and Alu elements in the p53-Mdm2-Mdm4
regulatory network.</article-title>
<source><italic>J Mol Cell Biol.</italic></source>
<year>2014</year>;<volume>6</volume>(<issue>3</issue>):<fpage>192</fpage>&#x02013;<lpage>197</lpage>.
<pub-id pub-id-type="doi">10.1093/jmcb/mju020</pub-id>
<!--<pub-id pub-id-type="pmcid">4092252</pub-id>-->
<pub-id pub-id-type="pmid">24868102</pub-id></mixed-citation></ref><ref id="ref-71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liao</surname><given-names>JM</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><etal/></person-group>: <article-title>New insights into p53 functions through its
target microRNAs.</article-title>
<source><italic>J Mol Cell Biol.</italic></source>
<year>2014</year>;<volume>6</volume>(<issue>3</issue>):<fpage>206</fpage>&#x02013;<lpage>213</lpage>.
<pub-id pub-id-type="doi">10.1093/jmcb/mju018</pub-id>
<!--<pub-id pub-id-type="pmcid">4034730</pub-id>-->
<pub-id pub-id-type="pmid">24740682</pub-id></mixed-citation></ref><ref id="ref-72"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>XL</given-names></name><name><surname>Jones</surname><given-names>MF</given-names></name><name><surname>Subramanian</surname><given-names>M</given-names></name><etal/></person-group>: <article-title>Mutant p53 exerts oncogenic effects through
microRNAs and their target gene networks.</article-title>
<source><italic>FEBS Lett.</italic></source>
<year>2014</year>;<volume>588</volume>(<issue>16</issue>):<fpage>2610</fpage>&#x02013;<lpage>2615</lpage>.
<pub-id pub-id-type="doi">10.1016/j.febslet.2014.03.054</pub-id>
<pub-id pub-id-type="pmid">24726728</pub-id></mixed-citation></ref><ref id="ref-73"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mercer</surname><given-names>TR</given-names></name><name><surname>Dinger</surname><given-names>ME</given-names></name><name><surname>Mattick</surname><given-names>JS</given-names></name></person-group>: <article-title>Long non-coding RNAs: insights into
functions.</article-title>
<source><italic>Nat Rev Genet.</italic></source>
<year>2009</year>;<volume>10</volume>(<issue>3</issue>):<fpage>155</fpage>&#x02013;<lpage>159</lpage>.
<pub-id pub-id-type="doi">10.1038/nrg2521</pub-id>
<pub-id pub-id-type="pmid">19188922</pub-id></mixed-citation></ref><ref id="ref-74"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ponting</surname><given-names>CP</given-names></name><name><surname>Oliver</surname><given-names>PL</given-names></name><name><surname>Reik</surname><given-names>W</given-names></name></person-group>: <article-title>Evolution and functions of long noncoding
RNAs.</article-title>
<source><italic>Cell.</italic></source>
<year>2009</year>;<volume>136</volume>(<issue>4</issue>):<fpage>629</fpage>&#x02013;<lpage>641</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cell.2009.02.006</pub-id>
<pub-id pub-id-type="pmid">19239885</pub-id></mixed-citation></ref><ref id="ref-75"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ponjavic</surname><given-names>J</given-names></name><name><surname>Ponting</surname><given-names>CP</given-names></name><name><surname>Lunter</surname><given-names>G</given-names></name></person-group>: <article-title>Functionality or transcriptional noise? Evidence
for selection within long noncoding RNAs.</article-title>
<source><italic>Genome Res.</italic></source>
<year>2007</year>;<volume>17</volume>(<issue>5</issue>):<fpage>556</fpage>&#x02013;<lpage>565</lpage>.
<pub-id pub-id-type="doi">10.1101/gr.6036807</pub-id>
<!--<pub-id pub-id-type="pmcid">1855172</pub-id>-->
<pub-id pub-id-type="pmid">17387145</pub-id></mixed-citation></ref><ref id="ref-76"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Idogawa</surname><given-names>M</given-names></name><name><surname>Ohashi</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><etal/></person-group>: <article-title>Identification and analysis of large intergenic
non-coding RNAs regulated by p53 family members through a genome-wide
analysis of p53-binding sites.</article-title>
<source><italic>Hum Mol Genet.</italic></source>
<year>2014</year>;<volume>23</volume>(<issue>11</issue>):<fpage>2847</fpage>&#x02013;<lpage>2857</lpage>.
<pub-id pub-id-type="doi">10.1093/hmg/ddt673</pub-id>
<pub-id pub-id-type="pmid">24403050</pub-id></mixed-citation></ref><ref id="ref-77"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huarte</surname><given-names>M</given-names></name><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Feldser</surname><given-names>D</given-names></name><etal/></person-group>: <article-title>A large intergenic noncoding RNA induced by p53
mediates global gene repression in the p53 response.</article-title>
<source><italic>Cell.</italic></source>
<year>2010</year>;<volume>142</volume>(<issue>3</issue>):<fpage>409</fpage>&#x02013;<lpage>419</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cell.2010.06.040</pub-id>
<!--<pub-id pub-id-type="pmcid">2956184</pub-id>-->
<pub-id pub-id-type="pmid">20673990</pub-id></mixed-citation></ref><ref id="ref-78"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoon</surname><given-names>JH</given-names></name><name><surname>Abdelmohsen</surname><given-names>K</given-names></name><name><surname>Srikantan</surname><given-names>S</given-names></name><etal/></person-group>: <article-title>LincRNA-p21 suppresses target mRNA
translation.</article-title>
<source><italic>Mol Cell.</italic></source>
<year>2012</year>;<volume>47</volume>(<issue>4</issue>):<fpage>648</fpage>&#x02013;<lpage>655</lpage>.
<pub-id pub-id-type="doi">10.1016/j.molcel.2012.06.027</pub-id>
<!--<pub-id pub-id-type="pmcid">3509343</pub-id>-->
<pub-id pub-id-type="pmid">22841487</pub-id></mixed-citation></ref><ref id="ref-79"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dimitrova</surname><given-names>N</given-names></name><name><surname>Zamudio</surname><given-names>JR</given-names></name><name><surname>Jong</surname><given-names>RM</given-names></name><etal/></person-group>: <article-title>
<italic>LincRNA-p21</italic> activates <italic>p21</italic> in
<italic>cis</italic> to promote Polycomb target gene expression and to
enforce the G1/S checkpoint.</article-title>
<source><italic>Mol Cell.</italic></source>
<year>2014</year>;<volume>54</volume>(<issue>5</issue>):<fpage>777</fpage>&#x02013;<lpage>790</lpage>.
<pub-id pub-id-type="doi">10.1016/j.molcel.2014.04.025</pub-id>
<!--<pub-id pub-id-type="pmcid">4103188</pub-id>-->
<pub-id pub-id-type="pmid">24857549</pub-id></mixed-citation></ref><ref id="ref-80"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoon</surname><given-names>JH</given-names></name><name><surname>Srikantan</surname><given-names>S</given-names></name><name><surname>Gorospe</surname><given-names>M</given-names></name></person-group>: <article-title>MS2-TRAP (MS2-tagged RNA affinity purification):
tagging RNA to identify associated miRNAs.</article-title>
<source><italic>Methods.</italic></source>
<year>2012</year>;<volume>58</volume>(<issue>2</issue>):<fpage>81</fpage>&#x02013;<lpage>87</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ymeth.2012.07.004</pub-id>
<!--<pub-id pub-id-type="pmcid">3493847</pub-id>-->
<pub-id pub-id-type="pmid">22813890</pub-id></mixed-citation></ref><ref id="ref-81"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhai</surname><given-names>H</given-names></name><name><surname>Fesler</surname><given-names>A</given-names></name><name><surname>Schee</surname><given-names>K</given-names></name><etal/></person-group>: <article-title>Clinical significance of long intergenic
noncoding RNA-p21 in colorectal cancer.</article-title>
<source><italic>Clin Colorectal Cancer.</italic></source>
<year>2013</year>;<volume>12</volume>(<issue>4</issue>):<fpage>261</fpage>&#x02013;<lpage>266</lpage>.
<pub-id pub-id-type="doi">10.1016/j.clcc.2013.06.003</pub-id>
<pub-id pub-id-type="pmid">24012455</pub-id></mixed-citation></ref><ref id="ref-82"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Mei</surname><given-names>Y</given-names></name><etal/></person-group>: <article-title>Reciprocal regulation of HIF-1&#x003b1; and lincRNA-p21
modulates the Warburg effect.</article-title>
<source><italic>Mol Cell.</italic></source>
<year>2014</year>;<volume>53</volume>(<issue>1</issue>):<fpage>88</fpage>&#x02013;<lpage>100</lpage>.
<pub-id pub-id-type="doi">10.1016/j.molcel.2013.11.004</pub-id>
<pub-id pub-id-type="pmid">24316222</pub-id></mixed-citation></ref><ref id="ref-83"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><etal/></person-group>: <article-title>LincRNA-p21 enhances the sensitivity of
radiotherapy for human colorectal cancer by targeting the Wnt/&#x003b2;-catenin
signaling pathway.</article-title>
<source><italic>Oncol Rep.</italic></source>
<year>2014</year>;<volume>31</volume>(<issue>4</issue>):<fpage>1839</fpage>&#x02013;<lpage>1845</lpage>.
<pub-id pub-id-type="doi">10.3892/or.2014.3047</pub-id>
<pub-id pub-id-type="pmid">24573322</pub-id></mixed-citation></ref><ref id="ref-84"><label>84</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mar&#x000ed;n-B&#x000e9;jar</surname><given-names>O</given-names></name><name><surname>Marchese</surname><given-names>FP</given-names></name><name><surname>Athie</surname><given-names>A</given-names></name><etal/></person-group>: <article-title>
<italic>Pint</italic> lincRNA connects the p53 pathway with epigenetic
silencing by the Polycomb repressive complex 2.</article-title>
<source><italic>Genome Biol.</italic></source>
<year>2013</year>;<volume>14</volume>(<issue>9</issue>):<fpage>R104</fpage>.
<pub-id pub-id-type="doi">10.1186/gb-2013-14-9-r104</pub-id>
<!--<pub-id pub-id-type="pmcid">4053822</pub-id>-->
<pub-id pub-id-type="pmid">24070194</pub-id></mixed-citation></ref><ref id="ref-85"><label>85</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>N</given-names></name><etal/></person-group>: <article-title>LncRNA loc285194 is a p53-regulated tumor
suppressor.</article-title>
<source><italic>Nucleic Acids Res.</italic></source>
<year>2013</year>;<volume>41</volume>(<issue>9</issue>):<fpage>4976</fpage>&#x02013;<lpage>4987</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/gkt182</pub-id>
<!--<pub-id pub-id-type="pmcid">3643595</pub-id>-->
<pub-id pub-id-type="pmid">23558749</pub-id></mixed-citation></ref><ref id="ref-86"><label>86</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qi</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>MD</given-names></name><name><surname>Ni</surname><given-names>SJ</given-names></name><etal/></person-group>: <article-title>Low expression of LOC285194 is associated with
poor prognosis in colorectal cancer.</article-title>
<source><italic>J Transl Med.</italic></source>
<year>2013</year>;<volume>11</volume>:<fpage>122</fpage>.
<pub-id pub-id-type="doi">10.1186/1479-5876-11-122</pub-id>
<!--<pub-id pub-id-type="pmcid">3665590</pub-id>-->
<pub-id pub-id-type="pmid">23680400</pub-id></mixed-citation></ref><ref id="ref-87"><label>87</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tong</surname><given-names>YS</given-names></name><name><surname>Zhou</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>XW</given-names></name><etal/></person-group>: <article-title>Association of decreased expression of long
non-coding RNA LOC285194 with chemoradiotherapy resistance and poor
prognosis in esophageal squamous cell carcinoma.</article-title>
<source><italic>J Transl Med.</italic></source>
<year>2014</year>;<volume>12</volume>:<fpage>233</fpage>.
<pub-id pub-id-type="doi">10.1186/s12967-014-0233-y</pub-id>
<!--<pub-id pub-id-type="pmcid">4155091</pub-id>-->
<pub-id pub-id-type="pmid">25169763</pub-id></mixed-citation></ref><ref id="ref-88"><label>88</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ding</surname><given-names>YC</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><etal/></person-group>: <article-title>Expression of long non-coding RNA LOC285194 and
its prognostic significance in human pancreatic ductal
adenocarcinoma.</article-title>
<source><italic>Int J Clin Exp Pathol.</italic></source>
<year>2014</year>;<volume>7</volume>(<issue>11</issue>):<fpage>8065</fpage>&#x02013;<lpage>8070</lpage>.
<!--<pub-id pub-id-type="pmcid">4270565</pub-id>-->
<pub-id pub-id-type="pmid">25550852</pub-id></mixed-citation></ref><ref id="ref-89"><label>89</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qi</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>MD</given-names></name><name><surname>Shen</surname><given-names>XH</given-names></name><etal/></person-group>: <article-title>Reciprocal repression between TUSC7 and miR-23b
in gastric cancer.</article-title>
<source><italic>Int J Cancer.</italic></source>
<year>2015</year>;<volume>137</volume>(<issue>6</issue>):<fpage>1269</fpage>&#x02013;<lpage>1278</lpage>.
<pub-id pub-id-type="doi">10.1002/ijc.29516</pub-id>
<pub-id pub-id-type="pmid">25765901</pub-id></mixed-citation></ref><ref id="ref-90"><label>90</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Young</surname><given-names>TL</given-names></name><name><surname>Matsuda</surname><given-names>T</given-names></name><name><surname>Cepko</surname><given-names>CL</given-names></name></person-group>: <article-title>The noncoding RNA <italic>taurine upregulated
gene 1</italic> is required for differentiation of the murine
retina.</article-title>
<source><italic>Curr Biol.</italic></source>
<year>2005</year>;<volume>15</volume>(<issue>6</issue>):<fpage>501</fpage>&#x02013;<lpage>512</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cub.2005.02.027</pub-id>
<pub-id pub-id-type="pmid">15797018</pub-id></mixed-citation></ref><ref id="ref-91"><label>91</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>EB</given-names></name><name><surname>Yin</surname><given-names>DD</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><etal/></person-group>: <article-title>P53-regulated long non-coding RNA TUG1 affects
cell proliferation in human non-small cell lung cancer, partly through
epigenetically regulating HOXB7 expression.</article-title>
<source><italic>Cell Death Dis.</italic></source>
<year>2014</year>;<volume>5</volume>(<issue>5</issue>):<fpage>e1243</fpage>.
<pub-id pub-id-type="doi">10.1038/cddis.2014.201</pub-id>
<!--<pub-id pub-id-type="pmcid">4047917</pub-id>-->
<pub-id pub-id-type="pmid">24853421</pub-id></mixed-citation></ref><ref id="ref-92"><label>92</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>M</given-names></name><etal/></person-group>: <article-title>Upregulation of the long noncoding RNA TUG1
promotes proliferation and migration of esophageal squamous cell
carcinoma.</article-title>
<source><italic>Tumour Biol.</italic></source>
<year>2015</year>;<volume>36</volume>(<issue>3</issue>):<fpage>1643</fpage>&#x02013;<lpage>1651</lpage>.
<pub-id pub-id-type="doi">10.1007/s13277-014-2763-6</pub-id>
<pub-id pub-id-type="pmid">25366138</pub-id></mixed-citation></ref><ref id="ref-93"><label>93</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><etal/></person-group>: <article-title>Double-negative feedback loop between long
non-coding RNA TUG1 and miR-145 promotes epithelial to mesenchymal
transition and radioresistance in human bladder cancer
cells.</article-title>
<source><italic>FEBS Lett.</italic></source>
<year>2015</year>;<volume>589</volume>(<issue>20 Pt
B</issue>):<fpage>3175</fpage>&#x02013;<lpage>81</lpage>.
<pub-id pub-id-type="doi">10.1016/j.febslet.2015.08.020</pub-id>
<pub-id pub-id-type="pmid">26318860</pub-id></mixed-citation></ref><ref id="ref-94"><label>94</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>L&#x000e9;veill&#x000e9;</surname><given-names>N</given-names></name><name><surname>Melo</surname><given-names>CA</given-names></name><name><surname>Rooijers</surname><given-names>K</given-names></name><etal/></person-group>: <article-title>Genome-wide profiling of p53-regulated enhancer
RNAs uncovers a subset of enhancers controlled by a lncRNA.</article-title>
<source><italic>Nat Commun.</italic></source>
<year>2015</year>;<volume>6</volume>: 6520.
<pub-id pub-id-type="doi">10.1038/ncomms7520</pub-id>
<!--<pub-id pub-id-type="pmcid">4389233</pub-id>-->
<pub-id pub-id-type="pmid">25813522</pub-id></mixed-citation></ref><ref id="ref-95"><label>95</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Allen</surname><given-names>MA</given-names></name><name><surname>Andrysik</surname><given-names>Z</given-names></name><name><surname>Dengler</surname><given-names>VL</given-names></name><etal/></person-group>: <article-title>Global analysis of p53-regulated transcription
identifies its direct targets and unexpected regulatory
mechanisms.</article-title>
<source><italic>eLife.</italic></source>
<year>2014</year>;<volume>3</volume>:<fpage>e02200</fpage>.
<pub-id pub-id-type="doi">10.7554/eLife.02200</pub-id>
<!--<pub-id pub-id-type="pmcid">4033189</pub-id>-->
<pub-id pub-id-type="pmid">24867637</pub-id></mixed-citation></ref><ref id="ref-96"><label>96</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>S&#x000e1;nchez</surname><given-names>Y</given-names></name><name><surname>Segura</surname><given-names>V</given-names></name><name><surname>Mar&#x000ed;n-B&#x000e9;jar</surname><given-names>O</given-names></name><etal/></person-group>: <article-title>Genome-wide analysis of the human p53
transcriptional network unveils a lncRNA tumour suppressor
signature.</article-title>
<source><italic>Nat Commun.</italic></source>
<year>2014</year>;<volume>5</volume>: 5812.
<pub-id pub-id-type="doi">10.1038/ncomms6812</pub-id>
<!--<pub-id pub-id-type="pmcid">4284803</pub-id>-->
<pub-id pub-id-type="pmid">25524025</pub-id></mixed-citation></ref><ref id="ref-97"><label>97</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Sawada</surname><given-names>G</given-names></name><name><surname>Kurashige</surname><given-names>J</given-names></name><etal/></person-group>: <article-title>Amplification of <italic>PVT-1</italic> is
involved in poor prognosis via apoptosis inhibition in colorectal
cancers.</article-title>
<source><italic>Br J Cancer.</italic></source>
<year>2014</year>;<volume>110</volume>(<issue>1</issue>):<fpage>164</fpage>&#x02013;<lpage>171</lpage>.
<pub-id pub-id-type="doi">10.1038/bjc.2013.698</pub-id>
<!--<pub-id pub-id-type="pmcid">3887297</pub-id>-->
<pub-id pub-id-type="pmid">24196785</pub-id></mixed-citation></ref><ref id="ref-98"><label>98</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><etal/></person-group>: <article-title>The human long non-coding RNA-RoR is a p53
repressor in response to DNA damage.</article-title>
<source><italic>Cell Res.</italic></source>
<year>2013</year>;<volume>23</volume>(<issue>3</issue>):<fpage>340</fpage>&#x02013;<lpage>350</lpage>.
<pub-id pub-id-type="doi">10.1038/cr.2012.164</pub-id>
<!--<pub-id pub-id-type="pmcid">3587705</pub-id>-->
<pub-id pub-id-type="pmid">23208419</pub-id></mixed-citation></ref><ref id="ref-99"><label>99</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hung</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>MF</given-names></name><etal/></person-group>: <article-title>Extensive and coordinated transcription of
noncoding RNAs within cell-cycle promoters.</article-title>
<source><italic>Nat Genet.</italic></source>
<year>2011</year>;<volume>43</volume>(<issue>7</issue>):<fpage>621</fpage>&#x02013;<lpage>629</lpage>.
<pub-id pub-id-type="doi">10.1038/ng.848</pub-id>
<!--<pub-id pub-id-type="pmcid">3652667</pub-id>-->
<pub-id pub-id-type="pmid">21642992</pub-id></mixed-citation></ref><ref id="ref-100"><label>100</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>: <article-title>Activation of p53 by MEG3 non-coding
RNA.</article-title>
<source><italic>J Biol Chem.</italic></source>
<year>2007</year>;<volume>282</volume>(<issue>34</issue>):<fpage>24731</fpage>&#x02013;<lpage>24742</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M702029200</pub-id>
<pub-id pub-id-type="pmid">17569660</pub-id></mixed-citation></ref><ref id="ref-101"><label>101</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Bi</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>X</given-names></name><etal/></person-group>: <article-title>Up-regulated long non-coding RNA H19 contributes
to proliferation of gastric cancer cells.</article-title>
<source><italic>FEBS J.</italic></source>
<year>2012</year>;<volume>279</volume>(<issue>17</issue>):<fpage>3159</fpage>&#x02013;<lpage>3165</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08694.x</pub-id>
<pub-id pub-id-type="pmid">22776265</pub-id></mixed-citation></ref><ref id="ref-102"><label>102</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>V</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Chakraborty</surname><given-names>A</given-names></name><etal/></person-group>: <article-title>Long noncoding RNA MALAT1 controls cell cycle
progression by regulating the expression of oncogenic transcription factor
B-MYB.</article-title>
<source><italic>PLoS Genet.</italic></source>
<year>2013</year>;<volume>9</volume>(<issue>3</issue>):<fpage>e1003368</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pgen.1003368</pub-id>
<!--<pub-id pub-id-type="pmcid">3605280</pub-id>-->
<pub-id pub-id-type="pmid">23555285</pub-id></mixed-citation></ref><ref id="ref-103"><label>103</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>HT</given-names></name><name><surname>Shi</surname><given-names>DB</given-names></name><name><surname>Wang</surname><given-names>YW</given-names></name><etal/></person-group>: <article-title>High expression of lncRNA MALAT1 suggests a
biomarker of poor prognosis in colorectal cancer.</article-title>
<source><italic>Int J Clin Exp Pathol.</italic></source>
<year>2014</year>;<volume>7</volume>(<issue>6</issue>):<fpage>3174</fpage>&#x02013;<lpage>3181</lpage>.
<!--<pub-id pub-id-type="pmcid">4097248</pub-id>-->
<pub-id pub-id-type="pmid">25031737</pub-id></mixed-citation></ref><ref id="ref-104"><label>104</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>MH</given-names></name><name><surname>Hu</surname><given-names>ZY</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><etal/></person-group>: <article-title>MALAT1 promotes colorectal cancer cell
proliferation/migration/invasion via PRKA kinase anchor protein
9.</article-title>
<source><italic>Biochim Biophys Acta.</italic></source>
<year>2015</year>;<volume>1852</volume>(<issue>1</issue>):<fpage>166</fpage>&#x02013;<lpage>174</lpage>.
<pub-id pub-id-type="doi">10.1016/j.bbadis.2014.11.013</pub-id>
<!--<pub-id pub-id-type="pmcid">4268411</pub-id>-->
<pub-id pub-id-type="pmid">25446987</pub-id></mixed-citation></ref><ref id="ref-105"><label>105</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loewer</surname><given-names>S</given-names></name><name><surname>Cabili</surname><given-names>MN</given-names></name><name><surname>Guttman</surname><given-names>M</given-names></name><etal/></person-group>: <article-title>Large intergenic non-coding RNA-RoR modulates
reprogramming of human induced pluripotent stem cells.</article-title>
<source><italic>Nat Genet.</italic></source>
<year>2010</year>;<volume>42</volume>(<issue>12</issue>):<fpage>1113</fpage>&#x02013;<lpage>1117</lpage>.
<pub-id pub-id-type="doi">10.1038/ng.710</pub-id>
<!--<pub-id pub-id-type="pmcid">3040650</pub-id>-->
<pub-id pub-id-type="pmid">21057500</pub-id></mixed-citation></ref><ref id="ref-106"><label>106</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rezaei</surname><given-names>M</given-names></name><name><surname>Emadi-Baygi</surname><given-names>M</given-names></name><name><surname>Hoffmann</surname><given-names>MJ</given-names></name><etal/></person-group>: <article-title>Altered expression of <italic>LINC-ROR</italic>
in cancer cell lines and tissues.</article-title>
<source><italic>Tumour Biol.</italic></source>
<year>2015</year>;<fpage>1</fpage>&#x02013;<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1007/s13277-015-3933-x</pub-id>
<pub-id pub-id-type="pmid">26314857</pub-id></mixed-citation></ref><ref id="ref-107"><label>107</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>JU</given-names></name><name><surname>Agarwal</surname><given-names>V</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><etal/></person-group>: <article-title>Expanded identification and characterization of
mammalian circular RNAs.</article-title>
<source><italic>Genome Biol.</italic></source>
<year>2014</year>;<volume>15</volume>(<issue>7</issue>):<fpage>409</fpage>.
<pub-id pub-id-type="doi">10.1186/s13059-014-0409-z</pub-id>
<!--<pub-id pub-id-type="pmcid">4165365</pub-id>-->
<pub-id pub-id-type="pmid">25070500</pub-id></mixed-citation></ref><ref id="ref-108"><label>108</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jeck</surname><given-names>WR</given-names></name><name><surname>Sharpless</surname><given-names>NE</given-names></name></person-group>: <article-title>Detecting and characterizing circular
RNAs.</article-title>
<source><italic>Nat Biotechnol.</italic></source>
<year>2014</year>;<volume>32</volume>(<issue>5</issue>):<fpage>453</fpage>&#x02013;<lpage>461</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.2890</pub-id>
<!--<pub-id pub-id-type="pmcid">4121655</pub-id>-->
<pub-id pub-id-type="pmid">24811520</pub-id></mixed-citation></ref><ref id="ref-109"><label>109</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ju</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Fesler</surname><given-names>A</given-names></name></person-group>: <article-title>miRNA: the new frontier in cancer
medicine.</article-title>
<source><italic>Future Med Chem.</italic></source>
<year>2013</year>;<volume>5</volume>(<issue>9</issue>):<fpage>983</fpage>&#x02013;<lpage>985</lpage>.
<pub-id pub-id-type="doi">10.4155/fmc.13.74</pub-id>
<!--<pub-id pub-id-type="pmcid">3715138</pub-id>-->
<pub-id pub-id-type="pmid">23734680</pub-id></mixed-citation></ref><ref id="ref-110"><label>110</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tarasov</surname><given-names>V</given-names></name><name><surname>Jung</surname><given-names>P</given-names></name><name><surname>Verdoodt</surname><given-names>B</given-names></name><etal/></person-group>: <article-title>Differential regulation of microRNAs by p53
revealed by massively parallel sequencing: miR-34a is a p53 target that
induces apoptosis and G1-arrest.</article-title>
<source><italic>Cell cycle.</italic></source>
<year>2007</year>;<volume>6</volume>(<issue>13</issue>):<fpage>1586</fpage>&#x02013;<lpage>1593</lpage>.
<pub-id pub-id-type="doi">10.4161/cc.6.13.4436</pub-id>
<pub-id pub-id-type="pmid">17554199</pub-id></mixed-citation></ref></ref-list></back><sub-article id="report14211" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.5256/f1000research.8996.r14211</article-id><title-group><article-title>Referee response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Samant</surname><given-names>Rajeev</given-names></name><xref ref-type="aff" rid="r14211a1">1</xref><role>Referee</role></contrib><aff id="r14211a1">
<label>1</label>Department of Pathology, University of Alabama at Birmingham,
Birmingham, AL, USA</aff></contrib-group><author-notes><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>7</day><month>6</month><year>2016</year></pub-date><related-article id="d35e7266" related-article-type="peer-reviewed-article" ext-link-type="doi" xlink:href="10.12688/f1000research.8363.1">Version 1</related-article><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve</meta-value></custom-meta></custom-meta-group></front-stub><body><p>This article by Fesler <italic>et al. </italic>is a timely summary of the state of
the art of P53 related regulatory mechanisms with specific emphasis on colon cancer.
P53 is certainly the most critical node of oncogenesis and progression. With the
rapidly advancing information about the importance of non-coding RNA in the field of
cancer biology it is critical to establish an integrated picture that allows us to
make working models for regulation. The review has done a perfect job towards this
by providing two well designed figures. Overall it is a very timely review of this
ever evolving field. It is really appreciated that the authors have provided a bit
of introduction on what are miRNAs and what are Lnc RNAs. It will make it easy for
readers that are new to this field to appreciate the review.</p><p> It is intriguing that the authors have provided a glimpse of future directions for
the field. Overall I do not have any major or necessary suggestions. However I do
have a curious request. Authors may wish to provide insight on if there is any way
to integrate the miRNA based pathways to mRNA based pathways and if that has been
done for P53 field.&#x000a0;&#x000a0;&#x000a0;&#x000a0;</p><p>I have read this submission. I believe that I have an appropriate level of expertise
to confirm that it is of an acceptable scientific standard.</p></body></sub-article><sub-article id="report13581" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.5256/f1000research.8996.r13581</article-id><title-group><article-title>Referee response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Yuichiro</given-names></name><xref ref-type="aff" rid="r13581a1">1</xref><role>Referee</role></contrib><aff id="r13581a1">
<label>1</label>Department of Urology, San Francisco Veterans Affairs Medical
Center, University of California, San Francisco, San Francisco, CA, USA</aff></contrib-group><author-notes><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>20</day><month>5</month><year>2016</year></pub-date><related-article id="d35e7322" related-article-type="peer-reviewed-article" ext-link-type="doi" xlink:href="10.12688/f1000research.8363.1">Version 1</related-article><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve</meta-value></custom-meta></custom-meta-group></front-stub><body><p>In this review, the authors systematically summarize the interplay between non-coding
RNAs and the P53 pathway, with emphasis on how this affects gastrointestinal cancer.
The non-coding RNAs are focused on miRNA and lncRNA, and how these both regulate and
get regulated by P53.</p><p> The review is solid. The authors highlight each of the major miRNA or lncRNA
involved with p53 in gastrointestinal cancer in a concise way. Mutant p53 and its
effects on these noncoding RNA&#x02019;s are also discussed. They go into regulation of
noncoding RNA or P53, not only by direct but indirect mechanisms and include genes
involved in this regulation. They also touch up on noncoding RNA that have opposite
effects depending on cancer type and thus, not biased. References are appropriate.
The use of tables and figures highlight the key points made for each of the miRNA&#x02019;s
and lncRNA&#x02019;s and thus, make it easier for the reader to follow.</p><p> Comment: The summary section is not really a summary of what was discussed. It is
more of forthcoming ideas. Recommend adding a few sentences or a paragraph
summarizing what was actually discussed since this is a summary section. This can
then be followed by what is currently stated such as circular RNA, genomics
technology and computational approaches, and the rest, as future approaches.
Alternatively, the heading could be changed to &#x0201c;Future approaches&#x0201d; or something
similar, if permissible.</p><p>I have read this submission. I believe that I have an appropriate level of expertise
to confirm that it is of an acceptable scientific standard.</p></body></sub-article></article>